<SEC-DOCUMENT>0001213900-19-015152.txt : 20190809
<SEC-HEADER>0001213900-19-015152.hdr.sgml : 20190809
<ACCEPTANCE-DATETIME>20190809161529
ACCESSION NUMBER:		0001213900-19-015152
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190807
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190809
DATE AS OF CHANGE:		20190809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38543
		FILM NUMBER:		191013140

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k080719_optimizerx.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>WASHINGTON, D.C. 20549<BR>
____________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934<BR>
<BR>
</B>Date of Report (Date of earliest event reported): August 7, 2019<BR>
<BR>
<U>OptimizeRx Corporation</U><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><U>Nevada</U></TD>
    <TD STYLE="width: 30%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><U>000-53605</U></TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><U>26-1265381</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 69.12%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><U>400 Water Street, Suite 200, Rochester, MI</U></TD>
    <TD STYLE="width: 30.88%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><U>48307</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Registrant&rsquo;s telephone number, including area code: <U>248.651.6568</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7.05in; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">___________________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
        last report)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 23.05pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 467.85pt; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Emerging growth company&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Securities registered pursuant to Section 12(b) of the Act:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Title of each class</B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Trading symbol</B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 38%; border-bottom: black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Name of each exchange on which registered</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Common Stock</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">OPRX</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Nasdaq Capital Market</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01 Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 7, 2019, the Company held a conference
call to discuss the Company&rsquo;s 2019 second quarter earnings and other matters of business, a transcript of which is furnished
herewith as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Section 9 &ndash; Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A HREF="f8k080719ex99-1_optimizerx.htm">99.1 Conference call transcript dated August 7, 2019</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>OptimizeRx Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    Doug Baker</FONT></TD>
    <TD STYLE="width: 65%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Doug Baker<BR>
Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: August 9, 2019</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k080719ex99-1_optimizerx.htm
<DESCRIPTION>CONFERENCE CALL TRANSCRIPT DATED AUGUST 7, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="ex99i.jpg" ALT=""></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #00339A"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #00339A"><B>C O R P O R A T E P A R
T I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo, </B><I>Chief Executive Officer
&amp; Director</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Douglas Baker, </B><I>Chief Financial Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stephen Silvestro, </B><I>Chief Commercial
Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Miriam Paramore, </B><I>President</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #00339A"><B>C O N F E R E N C E C A
L L P A R T I C I P A N T S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #00339A"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #00339A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ryan Daniels, </B><I>William Blair &amp;
Company</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Andrew D'Silva, </B><I>B. Riley FBR, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Richard Baldry, </B><I>ROTH Capital Partners</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Eric Martinuzzi, </B><I>Lake Street Capital
Markets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Harvey Poppel, </B><I>Poptech, LP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ronald Chez, </B><I>Private Investor</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #00339A"><B>P R E S E N T A T I O N</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Good afternoon and thank you for joining us
today to discuss OptimizeRx's second quarter ended June 30, 2019. With us today is the Chief Executive Officer of OptimizeRx William
Febbo. He is joined by the Company's Chief Commercial Officer Stephen Silvestro, as well as the Company's President Miriam Paramore
and its Chief Financial Officer Doug Baker. Following their remarks, we'll open the call for questions. Then, before we conclude
today's call, I'll provide some important cautions regarding the forward-looking statements made by the Management during the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I'd like to remind everyone that today's call
is being recorded and will be made available for telephone replay via instructions in today's press release in the Investors section
of the Company's website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Now, I'd like to turn the call over to OptimizeRx's
CEO William Febbo. Please go ahead, sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you, Nadia and good afternoon everyone.
Thanks for joining us on the call today. In Q2, we achieved record top and bottom line results, along with strong gross margin
expansion over a year-ago quarter. In fact, it was our ninth straight quarter of revenue growth and we feel like we're just getting
started. This performance was driven by several key factors, but mostly by greater client engagement, partner-related revenue and
broader provider reach. Couple that with solid technology and a strong operational performance and we continue to build the ship
while sailing as a crew together, generating cash and profit while investing in growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a leading aggregator of the fragmented EHR
market, we have achieved unmatched physician reach to over 50% of the ambulatory market and an unbelievably strong pipeline for
additional reach. This means we have established the largest point of care network where hundreds of thousands of physicians and
patients interact every day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through our digital platform, pharma companies
can regain that critical access to doctors and their patients they have lost due to the evolution of our healthcare system, regulatory
changes and a greatly diminished role of the pharma rep. With OptimizeRx, pharma companies can provide important information and
patient savings precisely when it is needed, at the time and at point of care. The OptimizeRx platform and solution suite uniquely
delivers value for patients, healthcare providers, and life science manufacturers. Physicians are spending more and more time with
their EHR and less time with pharmaceutical representatives. OptimizeRx allows manufacturers to engage physicians at the point
of care within their EHR workflow. This is a powerful combination of value and convenience for the patient, physician, and manufacturer.
This helps create better health outcomes as well as a tremendous business opportunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the beginning of the year, we've expanded
our total addressable market by at least a factor of two by adding patient adherence and engagement to our solution set, so we're
now able to go after a much larger HCP messaging market estimated at more than $2.4 billion. Our addressable market opportunity
within our existing network is approximately $700 million if we were to have all our channel partners enabled with all our solutions.
So, suffice it to say, we are just getting started grabbing market share. It's hard to even use a baseball reference as we're probably
warming up to start the game. We also feel we're in a terrific position to continue to do growth for many, many years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we achieved another quarter of record
top line growth in Q2, our penetration into pharma is still at an early stage in many respects. We are connected to many manufacturers,
the top global manufacturers actually, but we're only just beginning to penetrate the market. In order to seize this huge market
opportunity, accelerate growth for the second half and 2020 through increased client penetration, we recently expanded our commercial
team. In Q2, we appointed Stephen Silvestro to the new position of Chief Commercial Officer. We also appointed new VP of Sales
to focus on the hospital market with three new VPs of sales to call on pharma. This all means we sort of see a lot of room for
growth ahead in this year and beyond, and we continue to attract and retain the right team in place to size the opportunity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Right now, I'd like to turn the call over to
our CFO, Doug Baker, who will walk us through the financial details for Q2. Afterwards, Steve Silvestro, our new Chief Commercial
Officer, will discuss our growth strategy to expand two enterprise level offerings. Then I'll come back and talk more about our
results, the market opportunity, and an outlook for the remainder of the year. Then we'll take your questions. Doug?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks, Will, and good afternoon everyone.
Earlier today, we issued a press release with results of our second quarter ended June 30, 2019. A copy is available to view or
download in the Investor Relations section of our website. We also filed our 10-Q with the SEC a short time ago.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the second quarter of 2019, our total revenue
increased 37% to $7 million. This was primarily due to increased sales of messaging products. We don't currently break out revenue
by service, but as we achieve greater scale, we plan to determine the best way to present our growth broken out by service offering.
As a result of our strong revenue growth, gross margin was 61.6% in the second quarter. This was up from 56.1% in the year-ago
quarter. The improvement was due to a favorable shift in product mix. We expect to continue to maintain gross margins of at least
60% on a quarterly basis in 2019.</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating expenses totaled $3.8 million,
up from $2.6 million in the same year-ago quarter. This increase was due to additional expenses related to our growth initiatives,
including our acquisition of CareSpeak Communications in October 2018. For the balance of the year, we expect our overall operating
expenses to remain at the second quarter 2019 level or maybe slightly above as we further implement our business plan and expand
our operations to grow the business in a very dynamic and active marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We've established a strong team as a base to
support our growth, so we don't expect our human resource cost to increase in step with revenues. As Will mentioned, we made additional
growth hires in the second quarter, including a VP of Sales to focus specifically on the hospital market, three additional commercial
VPs of sales and a Chief Commercial Officer to focus on enterprise arrangements and product expansion across our customer base.
We are investing in growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the second quarter, we also had a record
bottom line. On a GAAP basis, net income was $407,000 or $0.03 a share. This compares to net income of $281,000 or $0.02 per share
in the second quarter of 2018. Overall, the income resulted from increased revenues and gross margins, which offset the increase
in operating expenses. We expect to remain cash flow positive and GAAP profitable on a quarterly basis, although one-time expenses
related to investments in growth initiatives or noncash charges could result in a GAAP loss in any given quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Starting in the fourth quarter of 2018, we
began reporting two non-GAAP financial measures, non-GAAP net income and a non-GAAP earnings per share or EPS. We believe the use
of these measures can be helpful in assessing the Company's financial performance. We define non-GAAP net income or loss as GAAP
net income or loss, but with an adjustment to add back depreciation, amortization, and stock-based compensation expense. To arrive
at non-GAAP EPS, we take non-GAAP net income and divide by the number of weighted average shares outstanding on both a basic and
diluted basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the second quarter of 2019, our non-GAAP
net income was up 39% to $1.2 million or $0.09 per diluted share. This compared to $852,000 or $0.07 per share in the same year-ago
quarter. For additional information about our use of these non-GAAP measures and their reconciliation to GAAP, please see the related
section in today's press release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Turning to our balance sheet, cash and cash
equivalents totaled $30.5 million at June 30, 2019. This compares with $10.1 million at the end of March. The increase was due
to cash generated from operations and an underwritten offering that raised net proceeds of $21.3 million. We have continued to
operate debt-free and in fact, generated operating cash flow of $808,000 for the six months ended June 30, 2019. We expect to continue
to generate positive cash flow from operations on a quarterly basis for the balance of the year. We do not anticipate needing to
raise additional capital in the short or long term for operating purposes or to fund our internal growth plans. We are focused
on growing our revenue channel and partner network. However, as a company in a market that is active with mergers and acquisition
activity, we may have opportunities such as for acquisitions or strategic partner relationships that may require additional capital.
We will assess these opportunities as they arise with a view of maximizing shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This wraps up our financial results, so now
I'd like to turn the call over to Steve. Steve?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stephen Silvestror:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks, Doug. I'm delighted to join the team
on this call today and add my efforts to accelerate our growth. The addition of the three senior sales executives to our already
strong commercial team during the quarter demonstrates our focus on driving growth and expanding our enterprise level offerings.
The recent team members are each proven commercial sales leaders with strong records of delivering enterprise level solutions and
addressing unmet needs across the care continuum. Given how well Terry and the existing team have done to get us into most of the
top 50 manufacturers, we are very enthusiastic going into budget season for 2020 knowing we have a great deal of white space to
address in our existing customer base.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">By strengthening our commercial organization,
we're able to address the increasing demand of our core customers within the pharma industry. This focus also aligns with our passion
for improving adherence and ultimately better outcomes for patients. According to a recent PwC study, 52% of consumers with a high-deductible
health plan say it would be hard to meet their minimum deductible. This cost burden works against better outcomes, increases re-hospitalizations
and highlights the critical need for both greater adherence and financial solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are also witnessing the continuing migration
of pharma as an industry to digital solutions with an increasing focus on patient experience. Manufacturers are anxious to link
key puzzle pieces of the care continuum together to provide added clarity and empower physicians with the tools needed to help
their patients. This movement aligns with our unique ability to reach and educate physicians at the point of care, so they can
have more informed conversations with their patients about treatment options. Every patient presents a unique challenge and OptimizeRx
has the tools and solutions to help our pharmaceutical customers navigate these complexities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To more effectively and efficiently support
greater adherence and deliver financial solutions, we are in the process of integrating our core set of digital solutions into
a single platform and adding additional capabilities. This new integrated platform will enable unprecedented transparency into
patient medication and will provide access to patient provider pharma communication across the care continuum. It will enable pharmaceutical
and healthcare providers to address medication affordability and adherence faster and more efficiently. It will give pharma manufacturers
an enterprise level solution that reduces both cost and the burden on the patient, while improving patient retention and overall
care outcomes, all in a harmonious way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to a recent TransUnion Healthcare
analysis, last year about 59% of patients had an average out-of-pocket expense between $501 and $1,000 during a healthcare visit,
a dramatic increase from 39% in the year prior. These statistics reveal the critical need for providers, payers and the pharma
industry to offer patients more cost effective healthcare options that will ultimately reduce the costs for all parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our new platform will integrate seamlessly
into the workflows of some of the world's largest electronic health record vendors. This will enable the prescriber network real
time access to critical information from key pharma manufacturers. Direct EHR integration also means providers can, at the point
of care, deliver patient support and brand enrollment beyond e-coupons and now support adherence and outcomes. By linking data
with communications, pharma companies will be able to simplify messaging, provide greater transparency and more effectively reach
patients at the point of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Price transparency has become a major discussion
point across the industry in our country. It all ties together with adherence, communication and patient buy-in. Integrating our
solutions puts 100% focus on solving these problems and removing the barriers between clinical, financial and brand messaging for
pharmaceutical companies, barriers that prevent patients from achieving the best care outcomes possible. We're passionate about
helping to solve these complex problems as a team. We anticipate this new platform will be launched within the next couple of weeks
and it will set the stage for continued growth into 2020 and beyond.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I'd now like to turn the call back over to
Will.</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks Steve. Nice work, and thanks, Doug.
As I mentioned earlier, we're addressing a large market with significant penetration opportunity. As you heard from Steve, our
digital health platform addresses many pain points for all involved. In order to grow our market share, we are focused intently
on expanding revenue by client as well as expanding our solution set, EHR network and strategic partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aside from one other player in the market,
our EHR and ePrescribe platform currently reaches most of the EHRs that enable messaging within point of care. Our success acquiring,
integrating and expanding in to new EHR platforms continues to grow. We view them as our partners. We deliver needed content to
their members and ultimately revenue to their businesses. We are proud of our channel network and the team focused on it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the remainder of 2019, we plan to expand
our reach to physicians, pharmacies and patients, while increasing the utilization of our existing partners as they improve their
workflow and reach. This, by the way, is a continual process as technology improves and we are keeping our hand on the pulse of
new entrants and disruptive technologies to understand how they can be part of our platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Given the growth of both our client acquisition
and our channel network, we expect our messaging solutions to continue to grow and show strong results throughout the year. Last
quarter, we announced our technical connectivity to Epic and Cerner. Building on that capability, we further invested in the hospitals
and health system landscape by adding our new Vice President. By linking our platform to hospitals and health systems across the
country, we will have access to critical information from patient savings opportunities to medication adherence information. This
empowers patients with more affordable options and high-touch support programs after discharge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hospitals and health systems will also benefit
from reduced readmissions, increased patient satisfaction and improved quality of care. We expect these advancements to support
our stated goal of an additional 20% reach to physicians entering into 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to Q2, we announced a new partnership
and integration with NextGen Healthcare. Healthcare providers using NextGen Enterprise will have immediate access to our real time
cloud-based platform. Given the financial landscape in today's healthcare environment, it's more critical than ever that we work
together to bridge the communication gap between key stakeholders in the care journey, that is between providers, patients and
the pharma industry. Our partnership with NextGen, the leading provider of ambulatory-focused technology solutions, allows us to
empower providers with critical patient savings opportunities from the pharma industry. This, in turn, empowers patients with more
affordable medications and improved adherence. This marks a significant step towards improving quality care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Driven by these trends in digital health around
improving patient adherence and outcomes, there is clearly something much larger going on in our industry. There is an unprecedented
amount of capital being invested in digital health and health tech, with multiple acquisitions happening at the service level,
health IT level along with a fair amount of successful health tech IPOs. This all means that OptimizeRx is absolutely in the right
place at the right time, both operationally and strategically, to benefit from this investment activity and the opportunities they
represent.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June, Change Healthcare made their trading
debut. They are provider of revenue and payment cycle management and clinical information exchange solutions, connecting payers,
providers and patients in the U.S. healthcare system. In July, two other digital health companies, Livongo and Phreesia, both rallied
upon their IPOs. Then just last week, we saw Health Catalyst IPO on the NASDAQ. Every one of these health technology IPOs all soared
in their debuts. In fact, based on company filings, these recent IPOs are trading at anywhere from 8 times to 26 times sales. These
IPOs are attracting a lot of attention to the healthcare technology industry and we certainly welcome it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Affordability and disease management. Given
our unique access to the point of care, we believe strongly in our opportunity to scale both on acquisitions, which is a critical
piece of our growth story, as well as organic growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In summary, we continue to enjoy tremendous
market opportunity with a lot of room to grow. Being perfectly positioned between all key stakeholders, pharma, physicians and
patients, our platform enables multiple revenue streams and helps us on affordability and adherence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the remainder of the year, we'll remain
focused on generating revenue growth from our core solutions, expanding our network and hospital market, and seeking solid M&amp;A
and partnership opportunities to drive revenue for the future. All together, we can expect continued adoption of our health platform
across our entire client base. As we drive the growth of our pharmaceutical products and distribution network, we can expect that
our financial brand clinical messaging will also continue to grow along with our patient engagement activities. All this will drive
another year of terrific growth with strong margins and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I must say, seeing what is happening with the
new expanded commercial team in terms of building pipeline for the second half and 2020, the new solutions we will announce in
the coming weeks and some potential M&amp;A opportunities, I am more enthusiastic than I have ever been for our prospects as a
company. While we expect all this to drive continued growth in shareholder value, we know we need to keep getting the word out
about our success, so we plan to present at a number of investor conferences over the next several months. This includes the Lake
Street Best Ideas Conference, the Ross Technology Conference, the Stifel 2019 Healthcare Conference, all happening in the Big Apple,
so I hope to see you there. I will also be working to meet on various wealth management groups with the larger banks to increase
our reach to the retail investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Now with that, we'd like to open up to your
questions. Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you very much. If you would like to ask
a question, please signal by pressing star, one on your telephone keypad. If you are using a speakerphone please make sure your
mute function is turned off to allow your signal to reach our equipment. Again press star, one to ask a question. We will pause
for just a moment to allow everyone an opportunity to signal for a question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We'll go first with Mr. Ryan Daniels from William
Blair. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ryan Daniels:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hey, guys, congrats on the strong quarter and
thanks for taking the questions. Will, maybe one for you. You talked a little bit about your process of integrating your core set
of solutions in your single operating platform. Can you provide a little bit more background on that? What was the impetus to drive
that integration, number one? Then number two, how will that expand the value proposition for your client base going forward?</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hey, Ryan. Good question. As you know, over
the last few years, we've been very tactical with selling, going after brand level selling tactics. We've a lot of proof points
and we've been very successful measuring that and showing our value to the client base.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Now that we have an expanded team and new leadership,
what we're looking to do is go up a few levels to the groups within pharma that really allocate the total spend around a franchise,
a therapeutic area or a disease state, and by doing that, you don't tactically sell to them, you bring a platform, which basically
brings all these services together, which can be seen, measured and be very transparent. We have that with one client already and
we talked about it a little bit that last year and earlier this year, but we feel like that's going to make it easier for our clients
to understand the true impact of the total service suite and it's also how they make bigger decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You raise about the tactical. You still have
to sell tactically. You need to be connected tactically, but when you put these into one platform, it's actually easier for more
senior people in our client base to get their head around the true value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ryan Daniels:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay, and so we should think of this as something
that could potentially expand the sales per client or brand versus something that's going to be a pure price increase given the
integration. Is that fair?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Absolutely fair.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ryan Daniels:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay, great, and then I know you had talked
about expanding the provider base roughly 20%. NextGen obviously is a very strategic partner to accomplish that goal. So just an
update on where you sit in regards to reach of the ambulatory physician market at this point, kind of how penetrated are you in
that space?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Look, we're very penetrated and there's only
a few big ones left, which we've talked to. eClinicalWorks and Athena are out there and then there's a handful of smaller firms,
but we feel like we've got critical mass, and as we scale, as we've talked about, as you scale, you have more opportunity to go
to some of the bigger ones remaining. So feel very confident that we can probably keep that percentage moving forward through 2021
because there are some available and we have a whole team working on it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ryan Daniels:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay, perfect, and then final question. I know
at the start of the year, one of the bigger pharma companies pulled back a little bit on all their digital spend, given some of
the issues at Comtel (phon). I'm curious if you've seen them come back in the market either with purchases or back into the RFP
pipeline yet? Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks, Ryan. Yes, absolutely. The one in particular
is completely back and in the market and we're working hard with them. The others didn't pull back. They just started little later
in the year relative to our service, but yes, we feel we've got the tools in place. The relevance of affordability adherence has
never been higher, access to doctors has never been harder and we're sitting in a good place to really help them get to their clients.</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ryan Daniels:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay, perfect. Congrats again on your success.
Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks, Ryan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you. We'll next take Mr. Andrew D'Silva's
question from B. Riley FBR. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Andrew D'Silva:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hey, good afternoon. Thanks for taking my questions
and really congrats on the progress. Just a couple of really quick questions for me. As it's related to hospital penetration, now
that you're a partner with Medicom and technically integrated at Cerner and Epic, how are you seeing that track perhaps relative
to the ambulatory market? Is it starting to pick up in a way that you would expect?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Miriam Paramore:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hi. Yes, this is Miriam. We have one health
system live, seven facilities, maybe eight facilities in that health system live and we have two more big health systems going
online within the next 60 days. So we're beginning to get some traction there and start to get some experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Andrew D'Silva:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">That's really good to hear. Awesome, and then
as it relates to integrating into that single platform, I know you gave a little color in the last couple of questions about that,
but reading your Q and you had $1.5 million perpetual software license that was noted in there. Is that tied to the integration
to a single platform? Then if not, maybe a little bit of color on what it's going to be used for?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No, that's related to other channel integration,
not hospital system related.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Andrew D'Silva:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay, okay, perfect. Then just last question
for me, just as it relates to CareSpeak, I know you don't separate by segment, but can you give maybe a little bit of anecdotal
discussion about how that's progressing and how cross-selling has gone?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Yes, we almost don't even think about it as
cross-selling anymore. It's really the team addressing it. I can have Steve talk to that a little bit, but I've been very encouraged
by the collaboration. Keep in mind, when we bought CareSpeak, they really didn't have a sales team, the founder was selling. We
now have a fully trained commercial team working seamlessly with Serge, who founded the business. We're seeing access to more and
more clients that were purchasing our other solutions. Steve, I don't know if you want to add to that.</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stephen Silvestror:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Yes, I think that's a good articulation Will,
of exactly what we've got going on. I mean, when you think about the buyers and who are primary consumers and buyers of our solutions,
there's a high degree of overlap. Pharma is very much focused on the patient journey. CareSpeak obviously has several solutions,
which we are integrating real time into our platform and have integrated in some instances. All of those fill different pieces
along that patient journey. I think as we continue to commercialize new solutions or look at different acquisitions, we'll also
focus on the patient journey to check some of those boxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The long and the short of it is the cross-sell
is going extremely well. It's more organic than forced cross-sell, which is nice from a commercial perspective, but the synergy
is really good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Andrew D'Silva:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All right, great. Hey, thank you very much
for taking the questions and best of luck going forward this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stephen Silvestror:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you, Andy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you. We'll next go to Mr. Richard Baldry
from ROTH Capital. Please go ahead. Mr. Richard Baldry?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Richard Baldry:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks. I'm sort of curious, in terms of seasonality,
with the slower start for customer spend in the year, do you feel like the seasonality will change at all? Particularly, I think
about the third quarter, also there are more budget dollars to go into that quarter than maybe you've typically seen? Or it's been
more sort of sideways versus Q2? Or you feel like they would be more pent up for a year-end budget flush if anything?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hey, Rich. Yes, absolutely. I think there was
a little bit of a shift and we will see Q4 be bigger than we would expect and Q3 to be similar in nature, maybe down a little bit
compared to what is out there. But yes, we feel very strongly that we'll see a bigger pop in Q4 than in Q3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Richard Baldry:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Then, a lot of companies in this kind of fast
growth mode tend to do a lot of their sales hiring early in the year or late in the year, getting ready for the next year. You
started mid-year. How do you feel about sort of the team for looking out more to 2020 than the second half of this year? Do you
think there'll be more hiring to be done earlier in Fiscal '20 or at the end of '19 getting ready for '20?</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stephen Silvestror:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We're always looking for good talent. I think
we got a nice injection of energy, talent and reach with perfect timing because they're all now fully up to speed and hammering
on the market, which is good timing around our cycle, which is really September to November-December, in terms of RFPs for the
following year. We'll keep looking, Rich, through all of next year. You know what, as I've said before, we're going to be selective.
We're not just going to go grab whoever wants&mdash;so whoever wants to be on the team. We're in a good position to be selective.
Given Steve's network and background, we felt that bringing on the three new VPs was good idea and it&rsquo;s proven to be a great
idea.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Richard Baldry:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Maybe the last one be, you've got a lot of
growth levers, adding brands, adding reach, increasing adoption, broadening your offerings. When you think about maybe intermediate
term, are any of those more important than each other? Are there ones that because you directly control them, you feel better about
them maybe than ones that are less under your control? How do you really think about how you keep up this accelerated growth rate
across all those different levers? Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stephen Silvestror:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sure, Rich. So yes, I think we're in that position
where we really have to use all three. You never get everything you want, so I think focusing on all three allows us to get two,
sometimes all three, sometimes one, but it just gives us growth, which is what we all want. We are focused on all three. I think
we've set up organizationally really well to make those work. We've got the incentives in place to get people focused on the right
things. But yes, we focus on all three every day. That's why I always say I feel like we're just getting started. I mean, we really
have a startup feel. We just happen to be public and growing like crazy and profitable. The team is highly energized and we talk
about all three of those everyday.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Richard Baldry:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Great. Thanks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We'll take our next question from Mr. Eric
Martinuzzi from Lake Street. Please go ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Eric Martinuzzi:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks. I wanted to talk specifically about
the Q3 outlook. I know you just posted the quarter here where you had growth of 37%. That's obviously very impressive. As far as
where things go in Q3 and Q4, last year, if I look at the seasonality of the business, there was a sequential step up, both in
the revenue and the profits of the company. I'm just curious to know if you expect that same seasonality this year specifically,
we're at $7.4 million for Q3, which implies about a $400,000 step up. Do you see that in the pipeline? Then I have a follow-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hey, Eric. We don't&mdash;obviously we don't
give guidance and but we feel like there is plenty of revenue in the market to have continued growth. If anything, the thing we
would compromise is bottom line for growth, right, if we see an opportunity. So still feel very good about the second half of the
year.</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Eric Martinuzzi:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay, and then you spoke about NextGen in your
remarks. When I think about OPRX and where you sit in the ecosystem, there's two numbers that come to mind. One is the 370 plus
EHR partners and the other is the 500,000 plus healthcare professionals. NextGen in their PR specifically called out access to
55,000 healthcare practitioners and I'm just wondering&mdash;I assume it&rsquo;s probably wrong to go at it with a blunt instrument
and say, 500,000 plus 55,000 equals a nice 10% step up in your reach, but help walk me through what exactly that NextGen relationship
means as far as distribution for your clients?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sure, what's exciting about that one is a good
portion of those are cloud-based, which we've talked about as just a faster integration and access of information. Getting into
hard percentages I think is dangerous, getting into numbers of EHRs is dangerous because we could argue we're in all of them in
one way or another and it's a little misleading to an investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I think a couple things are important. One,
eprescribing is almost fully adopted and highly likely to become law federally, mainly as we talked about because of the opioid
compound issues and we are integrated at the point of prescribe. The entire world is talking about pricing and price transparency
and benefits and deductibles. It's a big problem, as Steve mentioned, as Miriam's talked about in the past and we are right square
in the middle.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I think that going back to what I said in terms
of our current network addressable market, the more important number is there's a lot of real estate that we have access to that
we can still sell solutions within the workflow. I would probably discourage you from focusing on a number of EHRs and number of
HCPs, because I think those numbers can be misleading, but I think the tailwinds are really eRx adoption, the amount of growth
opportunity we have and the team we have, frankly, as a tech team. A tech team selling into pharma is really, really powerful right
now.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Eric Martinuzzi:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay, and then one more, if I could, on the
market. You gave two numbers in the prepared remarks regarding, I think it was a $700 million kind of traditional and then a $2.4
billion TAM. The $2.4 billion TAM, does that include the traditional business of the financial messaging?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Absolutely. Yes, yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Eric Martinuzzi:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay. Thanks for taking my questions and congrats
on the quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks, Eric. See you in September.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you. Once again if you would like to
ask a question, please signal by pressing star, one on your telephone keypad. If you are using a speakerphone please make sure
your mute function is turned off to allow your signal to reach our equipment. Again press star, one to ask a question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We'll go next to Mr. Harvey Poppel from Poptech.
Please go ahead, sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Harvey Poppel:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you. Will, sensational quarter. Couple
of things I'll toot your horn on that you didn't toot your own horn on is you exceeded all the analyst forecasts. They're probably
not going to say that but you blew away the revenue forecasts that they had. Also you achieved, the company achieved membership
in the Select Russell 2000, which I thought was a major accomplishment. It puts you on the board for a more Investor, large Investor
interest.</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks. Thanks, Harvey. I appreciate that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Harvey Poppel:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Yes. Specifically on the growth, you stepped
up from I think was 27% in the first quarter to 37%. I think at the time you had your first quarter earnings, I recall your saying
that growth was going to accelerate during the balance of the year. But a few minutes ago, you said something like the third quarter
maybe down, though you have a big pop in Q4. Can you clarify the comment about Q3 may be down?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Yes. No. Sorry about that. So I think the second
half is going to be very strong. Q3 looks good. I don't think we'll see as big a sequential jump, mainly because there's that that
sort of this delayed push from the Q1. But I do think we're going to recoup all that that we didn't have in Q1. The clients are
probably going to go heavier in Q4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Harvey Poppel:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay. Good. On the raise that you did during
the quarter, you now have about $2.50 a share in cash, which is a pretty large sum for a company of your size. What can we expect
in terms of the next six months in seeing that deployed for the benefit of the shareholders?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Yes. So we're clearly focused on some M&amp;A
activity to expand the solution set or reach to patients or doctors and our investors can expect to see some activity there.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Harvey Poppel:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay, and do you think it's more likely to
be in the area of large&mdash;a single large acquisition or a series of smaller acquisitions?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Yes, transformative acquisition, I think is
risky for a company our size, so we're not focused on that. We're really looking for businesses that have proven what they do in
either the affordability or adherence space, but maybe lack the commercial team, which we now have and the commercial traction,
also a way to leverage our existing network in the EHR which no one else has except one other company in the market. So that is
our screen. That's our focus. It's more likely to be one or two smaller companies, which we can leverage through our commercial
team and network.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Harvey Poppel:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Is the&mdash;one of the criteria that each
acquisition has to stand alone and is being accretive to earnings?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Yes, we've talked about that. We believe within
the first 12 months that should be accretive. Yes.</P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Harvey Poppel:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Okay, final question. In your opening remarks,
you used the term that you have an unbelievably strong pipeline for even greater reach and so forth. How do you measure pipeline
in that context? When you say pipeline, is it pharmas? Is it EHRs? Is it different products? What does that word mean in that context?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Yes good question. As you know, I'm fairly
conservative on calls and even in meetings, I don't like to hype, so I did use a strong word for me and I believe it. That pipeline
for us is our CRM, so those are real numbers that we're seeing that our team is generating with clients that we know we have a
high likelihood of closing. I've seen increases in the last 30 days that I've never seen. I think Steve and his team are doing
a tremendous job. They&rsquo;re really leveraging the solution set and the access we have. I think this new positioning of platform
is going to go a long way with the clients because it really addresses some of the issues that they're focused on, which is reaching
their clients, being efficient, doing so and being able to measure it, so they know it's effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Harvey Poppel:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you. I'll step aside. Thanks very much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks for the support, Harvey. Appreciate
it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you. We'll take our next question from
Ron Chez, who's a Private Investor. Please go ahead, sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Good afternoon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hey Ron.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Doug, what did you say&mdash;I'm sorry. I missed
it about platform pricing. Somebody asked about pricing connected platform integration or platform availability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One of the analysts asked what that means.
Is it basically a focus of more revenue by manufacturer or just different pricing? The reality is it's a different pricing model
and it is more revenue by manufacturer. What we're doing is bundling our solution set to make it more efficient for more executive
people in the client base to make those decisions. To do that, you need multiple solutions, you need a platform, you need to be
able to measure it, all of which we can do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As you remember, Ron, a couple of years ago,
we had one solution. Last year, we had two, now we have four. They all interconnect and support each other within the spend. It's
all around affordability and adherence and patient engagement. It's a little bit of a positioning, but it's actually material because
we can go for larger revenue by manufacturer, which encompasses more brands and more disease areas.</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Does that mean you'll&mdash;I'm sorry, does
that mean you'll charge more for a coupon or that's going to stay steady?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It does not mean that. It means we're going
to have a macro price for the client and we will not get down to these sort of tactical commodity price negotiations. We're going
to move away from that over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You answered several questions that I had thought
about and you answered the question about expense increases versus growth opportunities. I wholeheartedly agree with that. But
you're going to pay, Doug's going to pay attention, you're going to pay attention to leveraging the expenses?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Douglas Baker:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Absolutely, Ron. We pay attention to that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">My last question is you cited several of the
recent IPOs and valuations of story stocks, and of course, I'm biased in this area, but what are you doing wrong&mdash;that&rsquo;s
you, Will, and I'm kidding a bit. What are you doing wrong about our valuation?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Again, I think these companies that are valued
under $1 billion are not supported by multiple large bank platforms and retail wealth. It&rsquo;s just not enough people know the
story. So I'm going to work really hard at that with our current banks. We have several other banks talking to us about all sorts
of reach into their networks. We just have to keep telling the story, working the conferences and delivering. I still believe within
the day if you deliver, people learn about it. It's just never as fast as you want. That's on me and the team to just get the story
out there better. Obviously everyone on this call can tell the story because you all care about what we're doing, enough to call
in, so tell the story, introduce me to anyone you want. So that is on us. I think we'll do a good job in the second half of that
coming off such great results for Q2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">You'll do better.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Every day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">One more question, and that is institutional
support. Would you kindly make an effort to reach retail investors as well? It's a good story for retail Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Absolutely, that's on our priority list as
well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Ronald Chez:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Good job. Congratulations.</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 30; width: 640">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks, Ron. Appreciate that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At this time, this concludes our question-and-answer
session. I'd now like to turn the call back over to Mr. Febbo. Please go ahead, sir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>William Febbo:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thanks, Nadia, and thanks everyone for joining
us on the call. If you can take just one thing away from this discussion, I hope it's the understanding of our potential for continued
strong growth and profitability, while generating tremendous value for all shareholders. Beyond all the financials, I hope you
can see that we've developed a unique corporate culture dedicated to do something truly valuable that really makes a difference
in people's lives, from patients to physicians and beyond.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When you can do this and grow and be profitable
and still be very early in this process, I believe this translates into an excellent opportunity for our stakeholders and I hope
you all agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Have a great afternoon and I look forward to
talking to you in the coming weeks. Thanks, Nadia. Wrap up. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Operator:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ladies and gentlemen, now, before we conclude
today's call, I would like to provide the Company's Safe Harbor statement that includes important cautions regarding forward-looking
statements made during today's call. Statements made by Management during today's call may contain forward-looking statements within
the definition of Section 27A in the Securities Act of 1933 as amended and Section 21E of the Securities Act of 1934 as amended.
These forward-looking statements should not be used to make an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The words anticipate, estimate, expect, possible
and seeking and similar expressions identify forward-looking statements, and they speak only to the date that statements was made.
Such forward-looking statements in this presentation include statements regarding estimation of total addressable market size,
market penetration, revenue growth, gross margin, operating expenses, profitability, cash flow, technology, investments, growth
opportunities, acquisitions, upcoming announcements and the need for raising additional capital. They also include the Management's
expectations for the rest of the year and adoption of the Company's digital health platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether because of new information, future events or otherwise. Forward-looking
statements are inherently subject to risk and uncertainties, some of which cannot be predicted or quantified. Future events and
actual results could differ materially from these set forth in or contemplated by underlying forward-looking statements. Risk and
uncertainties to which forward-looking statements are subject to could affect business and financial results are included in the
Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018. This form is available on the Company's website
and on the SEC website at sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before we end today's conference, I would like
to remind everyone that this call will be available for replay starting later this evening and running through August 28. Please
refer to today's press release for dial-in replay instructions available via the Company's website at www.optimizerx.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Thank you for joining us today. This concludes
today's conference call. You may now disconnect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right; font-size: 10pt">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">ViaVid has made considerable efforts to provide an accurate transcription. There may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference call. This transcript is being made available for information purposes only.</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-size: 8pt">1-888-562-0262 1-604-929-1352 www.viavid.com</FONT></P></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99i.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99i.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ') H # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^HW]H#QYX
M[TCXS>/].TGQWXVTG3;74M-2TT[2_%OB'3["U5_#FC3NEK8V>HQ6UNLDTDLS
M)#$BO-+)*P,DCLWD0^(_Q3(!'Q#^)I! (*^,_%I!!Z$$:GR#U![C![UV/[2?
M_);_ (D?]A/2_P#U&="K[/\ #;O_ ,(WX=_>2?\ (!T8<.X&!IMJ , ^E=F$
MPJQ4JB=1T^11=U%2OS-JVLHVM:_4\O,\Q>7QHR5)5?:RG&SFX<O)&,KW4)WO
M>UK*V]V?G_\ \+&^*G_10OB=_P"%EXM_^6='_"QOBI_T4+XG?^%EXM_^6=?H
MUO?_ )Z2?]_'_P#BJ-[_ //23_OX_P#\57;_ &2O^@A_^"E_\L/)_P!9)_\
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MO_RSK]#S)-GY99#WYD88R3W))S_*F^=+_P ]9/\ OMO\:7]DK_G^_P#P4O\
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M/-?IYC]#U=LC'KDY_/IBF,9&P1(X.<D[V(8=N,CM@'\?Q7]D6=I8AKS]DO\
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MOQ,J6TR2#?9YC-?^Z9YH?B7\4!U^(_Q'_P#"Y\5?_+2D_P"%F?$_O\2/B/\
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M&G_"E*WEA(__ #09OQ6J+1Y#"_9YE-?E@7^ISW_"S/B=_P!%)^(O_A=^*/\
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MQVXJEP+#KF<O_"./_P TD_\ $9:O_1.TO_#K4_\ F W_ /A9OQ,_Z*7\1O\
MPN/%0_\ <I1_PLSXG?\ 12OB)_X7?BG_ .6E<V8L9/RG ST.3CIQG'./<?6H
MF4-P .H.<=!T(P1G!P?;//44?ZBP;_Y&DEY_4XO_ -V0?C+52TX<IM]O[5J+
M\\ =3_PLSXF_]%*^(WX>.O%']=6'\J/^%F?$W_HI7Q&_\+KQ1_\ +:N1* 'D
M 'T!_P#U=J"BX.!SVY-7_J%'_H:R_P#"*'_S29_\1IJ_]$Y3\_\ A6J?_.\Z
M[_A9GQ-_Z*5\1O\ PNO%'_RVH_X69\3?^BE?$;_PNO%'_P MJY+/0$=?7'H3
MZGTJ%DV9(Y!(SU)Z=3^/H.^3WR?Z@Q_Z&LO_  BA_P#-)G_Q&RJM'PU33[/-
MZG_SN.S_ .%F?$W_ **5\1O_  NO%'_RVIO_  L[XF]OB7\1#_W/?BD?SU45
MQ@Y'\_ZCD#]0/I1@>@_(4?Z@QZYK/Y8*'ZXD%XV5>O#5/_P[U/\ YW'9_P#"
MSOB;_P!%*^(G_A>>*/\ Y:T?\+.^)O\ T4KXB?\ A>>*/_EK7#NI&6XQQP <
M]AV_/I_.F]N/Z_K^/;^HI_ZA0_Z&L_\ PCI__- _^(V5/^B:I_\ AWJ?_.X[
MO_A9WQ,_Z*7\1?\ PNO$_P#\MZ/^%G?$S_HI?Q%_\+KQ/_\ +>O/V0]5Z<?*
MQYSG'7H.W&,>F*CS@X. ?3.>H!'/IR/QXI_ZA4_^AK/_ ,(X?_-(?\1LJ?\
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M[''KZ''&1[9SBHN1PPP?T/T/^?QQ5BD*AA@C(_SZ4R2N0",$9![5"4*G Y4
MG)ZC')ST'KVJPRE,XR5_,CL!CDX&.OOSW-)P?<4TVMGZKHQ-)JS^7EYE$H"<
MJPZDG<.F3GC !QSWSVJ)DSR05;&?KU SZC\CQVXJZ\>3N3 ;&#[CMC.0,'GI
MSDY.:A9%8GCYERH;) !&??L?;^E7\6L7RRTNN]N^]UVM;1F4HN/IW_S_ $*3
M CAN.X(Z''.1U]LC^=-(+<-TR<$#!R,X.<GMG/R@'Z<&TRCE7 ..IP<8.#G/
M;KCKUJ!DQ@8W+VQU'7CKD@#O^G>J4EL]);6[ONNZ[&4HWU5K_@_)[_*R*Y4@
M<C*D<^H'<,/8=2/P%0M'_=^8'J#CIU&WIT]\]N15S '(QC!SSU_F#W]*C9 >
M4.UB<D<9/YYQW(P*M-IW1DTUH]'^#]+VN4&7TX([' Z8^7MSCID]NN.:C9<C
M!!'<'H<^V:NL@8GC#@8R.<8..F>_8D<CD'TB93T88[CG@^V1CGV_0\BJTE[U
M^62[=>RUNVNC\G\R)0O=K3RMI^'<H,N.&&1G@XX]><=#Z]N^>:A9, ]67IZG
M&.2?7OT_*K[(1DGH.YQT/'.1U/3CUX/)%0&,#E.G<9SZ\@D]>@QTJU+51EH_
MP;\NOIZ,RE'HU;^NAGLF.5&1_=';W7^O/?(]X2@.2ORMGG(X)[Y'?'J._?K6
M@4!R5X/<>IXQD=NG!QWS@U79 2<@JXQS^/4=B.HR1WJTVMM#&46O-=REWY&#
MCG([?7\/TZ57E101D [B2=W;!!^7&/[QZY. ![&^Z9X< 'J"#WY (Z=#VY[5
M XV_>&1V./IU';K^..W2K34K-NS77OT5F[_D3OH]5U7]6*!7'<,/3J1CG/ Y
MZ>F>?;-0E,<H,CNOI]/Z@]_3FM!HT5=RCGCGD\$@'@Y!X)[&JY4<D$AN>H.&
M_NYSQTQR.<$DU2E;26C[]'_7H8SI7VN^GFO/2RM^OD4&3JR8#$_,"/0\^AR/
M]['7UJL\8;<,8;KC@'/!YZY![GW(^FDT8/4$-TSSD#GG'?/3.,^IR#4+)GAA
M@\<^^."#T/T/H>,"MHSTL_*S.:4++5)K_)Z7VU_X)E.@48;ENF".,%CD@<XX
MW<DG&2,C@5#Y8')8E0/<'/'4C&1C/Y\] :U'7;PP+>AQUS],8],?3D\U3>/;
MAE^Z>@R<<@G@GGT[X// /%:=.Z,90=]%=?>UZ>71=>Y2&<#![>F2..WT[9!]
M\U"T71HSCGY@><@#C(X.1U'/?@8P*MN@)) P1@8/"\'J1C&>3C.>@."#490C
MYBH'(&01D9X'  '<=NASUJHR:TZ7^Y=;;?CU,'!/6/W?Y,H/'N]GX('H><[C
MUXR> 1SC@9-5G3LX]=K8XYQRI]1D>Q.,5JE0W;#<X; [''./7N#[XYJN\>.'
M^8'@=!Z[LX P",?0Y/.T$:IIJZ_K_@HQE!.^EGK\_7\?F9;(1UY7U],$8W?X
MC !'I59XR/NGY,Y( S\N.0>>AYR>3^/73>,ITR1CD 'CMWYP1NZYZ?*<CBNR
M=2G.?O+^9)YZ'H,<"J3L[K_A_4QE'I)6??K;[S/*8^Z".^TXZ#&=O/?W/4@C
M(R#"V#G'W@.A( &.N3[=\9_G5]HU;IP>O?J0,'&1C@<<>_-0.@/7"L#U/Z^@
M;@G'IGL36L9<VFS\OTZZ=3"4'9IK3OT\FOZW*3+D?,,>A!S^1Z?4>W(XJNR$
M9R-RYXZ9!)[GCKDC_P"MFKY!4 ."3UR,=R<=,?3IZ>M0L,=<$-R, D8X/?.>
MHQ]#5QDX[:I]'W[JW_!,)TKVLF^UMUW\M?F9Q0+D$$H<'YL<9X&>>F0,'&0>
MOJ87C)'R< G)&,X.>>"1U/)[YSUS6@\6!E03V ]!V[\@'L<_IBH&3/*D(<_-
MCOV'#+@>O09[^M;1DGJGK^*.:46KIJ\>_2WGM;\MM3, ;)&",=1\Q.3ZYXR,
M$?* #SP, !&16Y/4=".O?Z^M7&7=@#"OCD]B>AP.0<D9SCH ,^E9U:,X;)SC
M#8XYXP<8[@_AC.,U=VW=63\NOYZO\^QC*-E=7??R7RZ+JRJRGE6!P>,CI[8/
M8^F>]0LI4]ROKU(^N!Z],#^6:NXR"",@_49X]#R/\>>]1E"O(Y4=NX'/Y@<>
M_P"6*M36ST>S[:=WW_ @H,@ RH&.I'MZCU^G?CIW@*JQQG!Y(P,'G).<CGJ.
M/;.>M7V3G*8YZKT&?7V/3(X_.H"JLQX(?C))P>F.!R.![8_G5F$Z*=W'31Z=
MWT_RT*+ C(;.>0,@8)Z @X[]LG([^M-(WG).  "N, @'KG.1V]./KTMLN00R
MDC]"1Z'KSZ\<=:@*LO7) [Y.>G\0XX'J?Q'6FG_P#DE#HTTU^'RTOMO\]2NZ
M@=?F0XR3@X.>^ ,<XQU]S32@( &0 <C&/?U!]35@C)!R<$\CC!XX/3/8=\>W
M-1F, _)P>Z\X(^ISTR.E:*?1_?Y>9FXV=O*__#E('OD=N.O'.1R<YZ;<GN>N
M*&4$@DD$C QCG&3W!YZU8VH_5>GX8/<<$9Z?R]:C=-O*@!<#J2<-DCIR><@<
M59)4D0YQSCH&(]0#D$8^8$'' ''YPGCGJ._!RIXX/'J3CZ<YJZP4@!@6YSCN
M">F<8]<#U]ZBV-V *\E3N[9R.H/;'!SGO51ERZ=.W;T)E%2WT?=6_&_;IL5^
M#[TT<'!QCG';OG'IW./I4A7))4')(.>,$8&0<< CGWSUZTWOC'U]O\_KD$9'
M(U335U_PQC.&EG\GTOW7X[^>A&44DD$C/7:1C///(/)J/D<$8/\ /W'M^OK4
MY'4CKCVY].M-8*V P)YXX8<].O%,PE%Q?==TOOO;;_(BJ/RQDG<PR2?X>YS_
M ':D9&4Y+97//08!R!VSG."3G&">.!0.:!%;GHP(.!D?U'X@X[\4QE!'/8CE
M>IQGKD$?0#OM';-6F16.6&3C'4CC\#43*4R0,)D8YZ9P._O[T 5N0<'/L<<$
M=CD9 R,''N**F(!!'48Z<<CL-V-V/3GC ]*B*$<C)'?/4=.F>3DYZ]/I1_FO
MS0'O/[27_);_ (D?]A+3/_48T.OL3PT<>'/#H&?^0!HW.>O_ !+;7/?/4]^M
M?'?[27_);_B1_P!A+3/_ %&-#K[$\-@'PWX=R,_\2'1O_3;;5^&Y3_$K_P""
MG_Z7(_LKB57I83_K[6M_X*IFZK$=<G..IZ?G_P#6J6JH!7G@],\8Q[\?7GI3
M@P!&""?SKV[?<?)7<=-6N_;O<L44BG('3/<4M(M.X4444 -90?;\.M1L-IQG
M/&:FH(R"/6@F44_4KTW&/<9/0'(SD]CR.V,>E/(8,0%)7U_#TQZ\4E/;^OZL
M9ZP>NSZ="+8 #@G@=#G/ZXX_^O3*G(/)!YQ[8.,XS^?J*CVYY9<'/W@>>O Q
MS_N_K1;M]W];C:4M5:_57_S_ $0RCJ,4K#;G/ S@$_IS24B&M=5JKKKUTVT3
M\KW\K78S;S]T8QP3@XZ]NOX9[Y[FHG7#%NN< A<@] <\'ID?KU-6,=?<Y_0#
M^E-V\[@ &R03SR.G/X8/X5:E;?5?U]XNEI):Z7MNM[NVD4[/R3MK=D&0./<#
M'3OCCUQ[4C*KC''8G'7_ #Z5*XW '!!4$CI@]#ZY[>U1C@X(VD\X]O7I[?I5
M.*>L7KY6W%:4+?:7563ZZ.^K:7_#]+0;2F >GKVZG/TQW/3FBK!QT]0?R[_S
MJ$H5Y7D<\=QZ >H[<GCCWH4[74MR7&^L;:[JZZ_/2_HEV&U$R'JN/=>W  &.
MF,X[\?K4O^?Q'!HJS,K^Q!!]#_GG\*:54C&!TP.!QZ$>F.WI5AE##T(Z'N/_
M -?0U"05.&Z=F['V/OU]J *Q7;A2,@Y.>HZY[DG@],^U0E#DD889/ (! ))Y
MR0" <<>N#VJ^1D$'H>#4#1[>4&2>,>@]<]3R.Y[\5:DGI+KUV_%6MZW\C.4-
MVON\[ZZO;TVT*+(#DKP>ZG(!&,8QCC.!S['WJ,]P>",'GV.?7!'T-7'7<QPW
MS!?N\<X)ZY]S@\U$RALJV P]P2,@'CU&.HZ'H:=Y1UE[T>C2U^Y=^_3YF32>
MC6ZMY_E=%5ANXP 1T;U(XQ^1/&>/PJ$J-H!7Y2." ,8(ZCNN0<\@8YJRRD8R
M>!T;\Q@YSSZ^_O2'CKR,'.<<#].,9SUK1-/5/^O\_P C*47'I==_\UOIW^92
M9&';<.>1U '<X_7&._KBH67JPR>N1@Y/Y\YQV[C'XWBAQE#D<\'MZ =">/7V
M]ZA9"23T;G*GH<' /J"1@_3'7%6I)JTE==_+\_QZD-)[HHL@;D8#>N/T/J"!
MCVXQTJ!D&<,,$$D$=\CL??N/49[9K089&""".0.^,\D#.#T(_P .*@93CYAP
M.N1QVP>^/H>YQGU:O#KS1^]K[FV[]V]#*46O-=[?F9[)@8<9'3=]1R?]GO[>
M]0LI7W7\R/KZCM^6<]:T&0J.?F7&#Z@=\^HQ^/USQ"4[K@@GIGITZ'D8Z\<#
MTQTJTTU=.Z,90W:^XSRF.4]>5X'7GC.,8]#Q]#46U22<#)X.1V^A^E72F22I
MP>ZGIG)SD\X/4<=QS4+)N_V6'J.<>A]0>OYXP<UHI=):JUOZ>K9F4)$ )+<Y
MR01P0 <]2??'%0.A PP!4Y ;UX/(';CN#W'8U?91D!P.,X)Z'IG!X]LY J(Q
M!03G. 3C &<#C)'/7GGKWJM8VUNNO=7VZM_\,1*"EY/\]-/3U7J]M<]D([;E
M_,CIU]?P&>.<GFJYBP2R<C&-O([] .@QT QG QUK0(')4CN2N#V_ND#'."<=
M.W%0LG4AL'H1U&<\D^AYR<< ]<UI&5M4[KM_5['/*FT]%;IK?IU3:U^7KL9A
MB##=C#XR2!W&. "00<=#Z\@BJS1C;\V1SC:."?F[]#P6/'8 =ZU60,21\K]\
M_3@$>G3D#/XU Z C$BCC/TQD=.O(R,Y'7ICJ-4T]G\CGE!.]M'^>FUGHKZ:]
M.VIEB-@0"0!@G<,?E@]!W)Z=!QTIG4#(R" 3TP.A[_G[8JVT;+R/F7H<CL3D
M9(&.RY')R<'K4#1\$J>/[HZ8Q@@'U./Q)/0G(I:.ZW1C*.Z:L_3M\OR>WJBH
M\6#N7+ #!7.<C##ICH,_SSGM6>,'YAPV3E<#GD@@ <G!RV<9(R>Y T ".0#U
MP>,+GI@YR<\]1QTIK*"21@/W&>H]/RQR!UZYQ6L9\VCT?3T_S\C"4.ZNNCV_
MX/R,ETR3D;6&<>_3KZC@ ]Q^1J!D[,!UX8=,_CD@]O?L>U:DB9&'&.@4CL22
M#MX)R, \'N!CUJM&0/F *G&3D'!ZX...W;\1WJS&4&NEUZ?G;;^FC-9"@P%W
M+U]AR.#G/?GT';IQ 1@9494C( ZKGG! [=<8' &/>M!EV_=Y7KCDX]>3GY>#
MGJ03TJ%H_P"),#KG&.<D=.#GOQ^6.E7&=K)K3OY6TT_X/F82A;6*T73=_JW^
MFY0<=P >!\H^]U],>AS^%0LF[G!4^XQSVW#'L/?'0BKS)GE<!L_,/?.#R>1W
MZ<&H6'&&^4@^A([XQ^OY?2M==UN8R@G?2S_K2VWX&>Z=58'!)P0.<$YX//7@
M$8!YJ!DQE2-RD\$\;>,=^0>ISZD@=*T6 QAL8/3)ZXQU]#TXS4#H5!.=PQ@]
M.V3\P(Y&.ISGV[UK&?1[]'T?Y6?YG-.FU=I.W:WWV;W]+=;(S7C*C"+D9Z]Q
MGJ"<>IX[8],<UQG(Z^O.!^0'/!QU_P *TRA'*=,]#SC) ^7!.>Y(R/;TJN4^
M;<HPY!W*>V<DY/'1N"/T]-+Z/K?9]GW\]/.W4PE"[[/KI^FEO6Q2>,,<CAN#
M[$CU QGZY_,<&)ESPPP>QXYP0<J>?0'!_'.#5DAE.& ![=@<].OOD'Z'K3<!
M@0V".P[#W!X/X\8Y%6I-)7U7?JOG]^C,FK.SZ%$C!PP!]#C@_P"![8^GK4+K
M@<#(YW9(P!]#UXS5YE*CYL%>F?Y;@?U/3)J IC[HW*?X1SCZ9/0\YYZXQWJT
MT]41."FM=^C6_P!_W%$HI^Z1DG)!.1Z\#MS^'Z5&1P1C! Z=,$_3L?R/X5<9
M QW*1D <8P.<\YP3T/\ +-1.@/7@CH1G(^G )'MC!JCDG!PLGJFKWMI?MNU>
MUBH5!Y&%(]B <XZY ]./?OC@QNN!M?H<'(R!U]>V#CGWJP5(Z@=OFP<'KQU_
M+.1W'6FD=N-K'D?AGZ8.*I2MZ?U?7?S,7"UVOZ[Z]?D5BGRA5XYR<\YZ]?7G
M!Y]!Z5" 02 ,D?+@9Z D< 9  (Q]&7)JT492,'<.XXW?S'MZ]_8U$T:L>/E/
M);@'))[YR,@@_K6B:>QF5MI8Y7:O !4^HR>,'!X(/&:B=><$<@]1QGC(P2#P
M,G*]SDXZU;92IY^8 9#' P>01GCMT]2<4QQD#)QSD$#ZX&#['GWI[.Z!I/1J
MZ[%-@5ZXZ=>@SW_S[TE3E205*DCGG P>>#U^AJ$C&2.YSM ."".J\=2>W3.:
MUC.^CT?X??Y]OD92A;5:KMNU^;:>M^WHQGL1D$GK@@]2.IST]13#&22P(!/&
M#G 'L >O /USCK4F0??\/? SGW'^-(1CD =#QTST]![?K5F$H;M?<^]]=7:W
MI;2Q #GM@^ASD?F!WS^5*0#U&?K4K!6QR >Q&,_3W'MZU$0ZGD#&<9'3OS^)
M &/<<^H9_P!:IK\TB$QMDX*X))'![DGUI@.?8^AS_7K5GK3'7.#G&T'\>G'Z
M4?\  _- >V?M)_\ );_B1_V$]*_]1G0J^PO#;8\/>'@3Q_8&C8X[_P!FVOX^
MM?'O[27_ "6_XD?]A/2_T\,:$:^O_#O_ "+OA_\ [ .C?IIMJ*_#<I^.O_@I
M?^ES/[(XF=J6#MO[6M_Z;@;X(/0T$?I_^K^M0@D=S4H;.2.@('/7G'/7W].U
M>TCY2,D]':_YW'*Q!]#SVXQGWR/3O4BOUW'Z<?X"HB/P_P ^^:3D9)Y'MZ#/
M)SCGZ4]]M^WF'*T[QV[?GY%JBH0Q!&22/K4H.1FD.,E+R\A:***"@IC+GD#G
M///^/^?Z/HH$TFK,@((ZTA&:G(!!X&<<&HBA SQ_G\*#-Q:=UMO?M8CQR,X/
M) SSQU]N<#KD_CFH]A4=00!Z8QC\3G\*FP#U&::1C)&.AR,=?\_CUI[^H74E
M9[OK^7F0T4XJ&/'!XP P(P.N0#WY[4A&#CTI6L2XM;I-;=T_D)C(P,\C [GT
M_/\ "HV0%N=Q..#G '7J0/?C@G)Z]*DH/]1_/FFFU_P?S)U5K>\NJ>LM7O?1
M62O=6NU9+8K.I4G'3H/XCD@$CG&1P3GZ=LBC/&3SQG^O^?YU*5!YP6Y.5)XX
M&W(_(?F?6FM'T"X3.<\=<XX]R.WXXQ6GNRWWV\]!<J;O"RW36MM+Z:+5I[Z]
MB)DW'(.#P,]L>X_'^G%18(X88/7V/T^G?_ZXJ93D$\]>YSV'^?7UI2H;J/I[
M>X]Z5Y0M?5?UH+25TTE+K;O^.FVEV04=>M*5*Y.01G\0"<#([^G:DJTT]C-I
MK<A*%>G*@=SR,?S]A^'I30<_YY'UJQ3&3=R,!N.?4#L?;G\\>E,17*#!P.3G
MDYZ^I_K5<K_"_P!X\\#'3G@XYQCU]JM\@X/!_F/4>QQ]1WIK+N&/U[C/!Q[X
MSCWP:I2:TW3Z/]"913OT??\ SWT_JY092.H^7) /4XZC(QZ#!//4COFHFC('
MRDLN/N]\8['J3Z#WXQ5YE*9;)*G/!)/)Y'7@ 8(XQG(X)%1,F!E0!@$D8Z]/
MUX./K5:VO#;K&W7K;:SUU>M].B,I*VCMK]S[[^NI2^F<\=2W\CZ\\XIC+DDC
MAAU_NGCIGL<8YQV]*M,H?H2"![C\QP2.N/3G'-0E2IP< GD''##'/ QTXR.Y
M&><YJE)/39]5V^>WW,RE#K%?+OZ>?SV*S(< ,,'G:V<D'OS@?EW ]J@96& P
MSR<$#(.,]0.F0>F>OTJ^<'AL8(/MC&/4GGG@]L5"RLG.-P_4#/&>N?K[<]:M
M.WFNJ,^Z?S3_ .'*!0K]T%AVQR1_];'OU&>]1,G4C(;N#T/;'L??UJ\R$<I@
MKQ\H_(X[>Y!ZG/<U"RY'&%(ZC'Y@@<\=L5:5]8.UMUT[7:6EWZ]$9RAUC]U_
MR,]DR>X8'!XR<?CU']UNP]LU"Z9.#D$=".A)&>/7L2#[9K09 >HYZ9SSC.>"
M/7U]#WZ&!DQP^&4DXST!YZ^A.2>N,YQCC-1E=M6::Z/_ (&G4QE%/I9]_P#,
MH,I'# $'H<<$CU'8^GJ1Q4)0KG'*^AZ@8Y]<_3&><=JOM&>F-R_J!QC([\]_
M;FH"AZIC&,[<>@[>F>.N><FK4FMNNZ>QDTUN4=BMD_,,GIP.1QZ9'3UJ%X\9
M8\#HNWDX&2..G SG/Z8S5YDS\R]1U'0$^_H?K[9Z5"RAOE;((YQT/0CWXY_S
MR*TCKK&R:W72W>R\_,EI-6?_  5Z=F9[+GA@00?O#H",C&?SX/7W!&860@88
M97^\/YD=5^O3/I6E(F0>1M R5QUP<G&,=L#\*K%",D#<N2,9RP[<YX//OQGN
M.CC/H_=EMZ_UYLPG3MJ_O6BOTO?7I?3HC-:/:/[R 8V^F#QZENPZ@<9([U6>
M(D%@""1DKU Q@')SDG R ,>ASS6H4(&Y>0>=I]S_  G@ 8(P,=L8S5<QCED[
MCD>H X QT/7UY)S6\9)[[]SGE#HUZ/\ RWW,MD+(>=H! YY).1@GKQD^V>N<
M&H0CY[#CUR.W88P3UZ^M:3QA@1C;ACD XSSU/&>HX_'%5O*8-@D8P?F&1R".
MF<<YSDCLQ'&1FS"4;;[/;_)[:Z7[%-@K 9!Y&01U'3//8<\]L?A4+QE3NSN'
M3D9 ';CJ3NP,Y.03TXJRR8&X<KCIW Y&?0X!/TR>3@4P<$D<].,@L<9Z8/09
MS^?3K5QFUH[O\_.]]_\ )&,H=4M.W];F<\>W++TSR/;H"#P"3QW[DGOBLR9)
MQE2<$\9'3T/'8<YYYP3T.N8\_,!Z?+U '3*]LXY[D\@'FJS1ASC&UEZXX.#G
M )&.,C@8]^^:U\S&4%TW[7_+:W](RW3/!&U_7'7Z$$9'H,\8Y'!J!EQPP+'L
M1UP>N#QC&.?PR3U.BRY&&![8;ISC/U!Z^V._-0.NW@X*G(&?7L&]?_K>M4I-
M>:[7Z7UMKIY&$H)MWT?];_\ #[&<RA0"0"G13U.#R!@^W?/.*C9<9(R0!D].
MV?I5TQ8.5&1SP23@<8 R3CH!Q^N!F!H\_,I/KMR<8XRH&=O(R,$<$CGBM8R4
MEITW7;>WEK8PE&^CW7W_ *Z-%%HPV2O?G'0$C]0>.H[]:KLF21C:V3\V#SC.
M,\8/'?)/0UI;0PX !S^6/ITXYZ?49Z0LH8$,#C/7! X[@D8_+J*N,FO-=NOH
MG_F<]2GK?;L_T?>WRW^1F/'_  MDL>C #IT&< <9YP<X]:KM&4'.23T(Z'\,
M<8S@<\UI.FWJ 1].&ZD ]@0![CD\=JA9<<??4Y[Y([G///?ITQTZ5LG=76JW
M\G8YY15[22O:R?D^WS\MS.R3Z$'V.,?7H?3BHVC[H<>H['&, >G3!X[^U73$
M 2RX([+VY.> .,#CGTR.1@56!.2",$8[YZU2;3O%=-5T\^VG;L92BXJ^EOZM
MN5&0'./E89[<'GG/3<.O/;.>M1$=F&#UZ_J#W_Q_"K[*&'/!['N.G3ZXY]N*
M@=.0' (]<<9(/ ]_\]:TC)/R?;_(AI-6:NNS*#KCY3R&&!U)]\G';L?Z@FH6
MC/\ "2?8_P PW/<<@]CZ8J^RE>O*^OIT'S?7./YU"Z?Q#/ 'RC&#UY_7]*HY
MJE&UW'56;:].WK;^D4AV(///4>O/(X]OP_"HRN<E1S_$"<#)].N.<D_YQ;9-
MW(^5N_3GV;]/<"H"#G&0&Q[$,.<$>W7W'>J3:>]OZV?E^1S2C?R?]:/T]-R!
MESE6&. >#VSP<_45&4P/DY)(SN.>!GH>W)JR5R=I!.<8;N,#/!QP>#^?(/>,
MJR]<$8Z@?7.>>V,]._'0UHI)[[_GZ&;5G8JCY01SA<+@<\C/ [D\$'UP,#FH
MMIZH,KC^(X(()SU'IC_)JT8SG<C8)))SSU.1CZ<U$5VD*3@Y5OER-W;!')/0
M# Z\50BHR<DX.[/^]@X! _$'D\<#'H:9R#@@@XSV(_,5=9 P)  8XP>O (]/
M4#\CBH&P05)&1D=<<@D9]15QG;1W:[[M?\#T(E!/5:/\&^[5OOM_P\)&?T_3
MFFG!!# _@#Z\$8S['KP:>5(R?X0>1W QG/N/8<C/H*2M4[ZHPE%-V>C79J_>
MW7O<@V-U4Y'8$]O7.,_A[^U,)RI(]#_*K'3GD@ \<<=/IZ>Y_6FNF>1@'^+_
M &ACO[C''ISZT?U^*,FG%I/Y>>OG;7:_FSV;]I+CXX?$<G@?VEIO/_<JZ(/Y
M\?6OKWPY_P B[X?_ .P%H_\ Z;K:OD']I, _&_XD ]]2TO\ ]1C0J^N?#S@>
M'?#XR?\ D!:/T!Z_V;;=3_\ 6K\.RB+=2O;^2G_Z7,_L;B?6E@U>S=2LD]/^
M?4-KW5]]]-&;PS@9X/<>AI,#.<<TF2<\$$>N.3SSP2.33CQ^GZG%>TU\O(^/
MOW5FK>COM9O>^G3>Z\R16[' P#R3[T_(/<']:@I02.E(TC.UD]NY+M P0.1[
MG_Z].5L'H,C/&?PS_D=Z:&!Z<@$ GW..V/<=Z4CN/?WZX^GI3O??Y/\ 0MI2
MU35UL_T)@^<YP/J:?57)!.00.QQQ^A8_GBI0YR,GCOQ_A2%S-:2^_I^FQ+10
M"#R**"PHHHH C9>I&3D]/SS3"".H(^M3TU@"/?!QS_D4$2A>[6_8A(S_ )].
M:81DX(SZ9X!XSU ZCGMT_64J1R1^HII&?\X_E33[D)\NC6CW37]=B$IM ZGU
M/TQUIM3$?E@YR3[?4^O QGUZ5%M/51CI\NTC\<DX'!Y^@'7H6&XIJ\=NW5"4
M9XST[_3\_2E((.#2'D$>M(BVM^NS\TKV3OM:[:M;SNB%ERPR<$*  HSGKZ]Q
MR:C.58YZ ##-P#G!(/;/T].]6CGMZC\L\_I4;+D\Y*D@@+PV<8SGZ9X]_;G1
M2OH^NE_\Q.TE:22>U];-O7W;VNNVFKNK:$0]3CIR1T_S_GO3'0DEE/..G8GG
MGZ_S^M2LA& @SD'(8]N,>F#R>.GO3%.<GG\0!V_K_P#J HY;.\?Z]-Q/16DD
MX][O3:U[66WGT=M2 9P,@@^A!'KZ_2EJ9E#>Q'0CK_\ 7'L:A*LIR>F< ^O!
M[=OKUR,=",4I)[Z-?UUZD2CU6J?1=/\ @"$9R#T(Z>_KG_/2H64KZD>N.G^]
MZ8]>F*GHJB"O41B&2P^]@Y/J3S^ S]:L-& ,H,$=N@/_ -?W]L=*9W(/!&,]
M^O3GZ4+1W6C[B:35GL4RN[[PVMVXPV.O0]>XZ8ZU"Z\[6&5R.2, \ ]<8R.1
MQC([YJ^RAL'&2. ?3/!/OCKCOC ZU"RLI^;!7Z=\ X R3S\W)].HSBKO&6]H
MR6TNWI?KJ]S.4&M5JNW5>2[_ )[E%D*@Y^9<<Y'('3D<Y'KZ#.<TP */E/'7
M  P3^ Y_G5MDV@%<E<$G)[#&, ^V>/SJ(H&Y4@'IQR/Q [^_7@#I5*33M)6[
M2UM\V^K_ ,^QE**EOO:R>NGX_F56 )++][&2IQNQP#@=1D <=#QW(J)EW8R&
M4C.,C&1QGKU[5:P0>F#GYAGC!''J/3D#J"/6D(#<,/4@@G/;/.![<<@_@*OS
M1DTUNGZVT\M=OET>AGL"05((/Y ^N#SP#@^M1%2,]2.>O./J3U!Z^W(-7F7&
M X!&>"<8..^.V<]/KZ5"R$9QRO7D\@8Y^N><?EZ5=XRMS:25K/MYZZ+[K>I#
MBI;W*+)@90<#^$=\XR1ZG@<=\<<FJ[)G)!VGD\\ GJ0P)X8Y[<X&1QQ6@R\;
MEY/7!P.OOT&!4+("23N!QCCCIW([XS^(Z9JN9Q^*[3>C6N[Z[)>7S[&,H]&M
M.GF9[ID]<,..G7TR/3/0CWP:A9?X7'T(Z9YQ@]CU(%7V3J''7H1['/![>N.H
M'KVA92,AAE>F?S.3Z$8Z^O3%692@UMM^)GLI7.1N7ID=<$<Y Z <\_2H3"I)
M(.!Z#&!C@_J.?>K[(PY'S+CD'J.Y//7V'OC'&:A9.Z?]\YX[ 8SG  R3CK5J
M2EI)*]K7]?N2]2+M;:&<R#) (&,CD]2IQDYQ@XY&#GCOBH60,<XVOWR.>!C!
M![=/R]:T'7>., YYR/4$$''?FF21Y P!W+-W R#GKR>I.!SR,<X-W<;7U71K
MIM:^EK:F<X<U[6UW3^;OUU;Z;;=S,=,_*ZX)'!ZC]1@G@$CZ&J[18X(RI.,C
MKUR!UX / X[ 9Y &BR]F&1ZXQ@^_<'&#NX'/;%0NF!_>4\$'DC/?/<9_$9]!
M6D9VZW6WIZ'-*#CM?L^_W(R7C &8R" ,D YQCG"D>P.?P( )J%E+*PQ@\$GH
M,@C@GCYL8XZGC Z"M1DXWJ.".5/4 9/ Z=SQ],<<57>,.#MROS<\=2"#D9]\
M9^A'&#6J=]482AU7W?Y;N_D9@!/16!QGH 2.AZ]0,C].*:Z*X 8X(R.<<'(S
M[9XQQ^'%7-CAMI&#C/4$ Y!Y//."1C!_AZXR(&4J3GD9.2/7)R,<<9SSP.1[
MFJ3Y7=?-=_4Q<4[]'WU^>A4=#@A@"G<G(! /&2,X['G&3P.]4WCVY*89>F./
MID $G&>HP.3QG.*U.><_,/H?Y%1GL>GXGH(7C/U3J0<Y 'KGD@$' Z].M:J2
MEM=>3_X<PE"^CT:Z_P!:6,DI_=Q[KD8Y]/?&"0 1U/ .:@9<Y(RK^AZ^V0?P
MY]*U&C5SE05.!VQP>G!XZ9Y)Y.<<C%5F7/##:P/4?W@.>><@9Z9YP>PJDVG=
M:/\ KU,91>SNUT?37;R_X)FN@/\ K!@CN0-I'8\\<9P<=,D \U 4 X89']X]
M#@'G/3)&2?QZ]:TF4CAAUZ$?A^([#GK@]NM9HR.#@H.F>, 9QSUXX&<=ZUC-
M;/1]^C\_+\NQC*/+JM5W[?=_5RFRXR#R,<\<8YSG\*KM'P2I)'4*,=CG@_AT
M/T[5>9&QD?,I'(/7:<9SZX!/3DXQR34>P8RH/L.@Z_R/4<\]:M:.Z[_U_6YA
M*":=ON\K??<S64$DJ,-G&2.O=@>A!SDXX&1TJO(@8XD^5A]TXZY[+G[Q! /&
M>H&.2*TW16R. P[CKQGKCG!SS_\ JJ!TP0"#C!.=Q]N >N<9R. >O8$;1FGY
M/HO\K[[:G+*#5^JZ]UO=6ZI=][;F4RLGW^ >AQQWR"<X'MSSUXS3>#QU!XZC
MI],Y ]R #V/(SH.F.'Y!R0PXQV(]1UX)ZY]JK/%M);G:?<<$GDG(]3GC@#/3
M S=T[WWWO^C\O34Q<-N7TM]^M]6WY%-D*\KEAZ'DCIT[G(S^@%0% <E<@YR0
M>F>X/<'^O7(JYD$G';L<YYSCH#Z=\#D<]<-9 W3@^OX\Y'&>^,]#T(K12:LI
M6M_,MG^GD^QG^'J9Y4$\@J??@XSZ>F<\^N??,+)P58#'..>P[^V./I5]ER0&
M!!ZY!Z#W/'?L,\X/O4+*1]X C. W'<>G;T^O3J*N]^M_Q,ITE+5:2[]_5?U^
M!GLI'JW^Z/F'H<#\1D<=CUIH '*\YSUXSGOTZ^O'/?FKC(0<C&W'.>N?;C&.
MGZU"R=2O7N.QP.,=,'C&>G.3TIW.64&M)+=?TKV7;:Y39><IR3U& =O4\G@C
MYB< ]/FXXIIY!!RN1CYA@\Y QGKGM[U9Y!/!SW'''IU(X/4?C3&7<3UW#@$
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M_*BYDU*+TO;^MU_F1$9X[@\[< G@>N>.>??%,*E>O?./7\>V?7'%3$9]L?\
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MZX(SC^7KC.:A9,G*X!R=P.>OTZAL]>GOT%7VC!Y!Q[= 3TYQR,\ @>F>M0E
M2<C:PSSWZ_0 @=.^<@\&K4E*]KZ=U8QE!/5;F>R@GD%6Q[9QS]01G/\ /CBH
M6!&588R,9'0Y'0$]^O7KC\*T'7LV <#!XZYXQGW'2H'7'#<J<C./8=<=._/'
M ZU:E;1ZK_A]KWMN9M-:,HF)L_*V!WR 3G\ .,8JNR%20.W4#_@/W?H#T/!Q
M[FK[)LY&2">>Y';/J<GKZ>E1.@;E3AB>3D],8QC/!X'Y<U:Z..J>C3?ZOY=/
M^!+BI:/3SLK_ #LDWZ-_D9[(#EEZ]P.AQVQV/Y=L@U7= Q(P5?U[D=NG4>X/
M:M*2/!& ,D]>>@(SG'KD]>GN<57=1T? /!!!^O0]CUXR>.A/6KC+MH^S_P C
MFG3:UVW\[V]-%\S.9#]T]><.?0G=@< DXP#R#U/UJO&R=,L#D\<D'/?GG=R1
MR3U_#5=".&Y4]&Z$'MD=CG."/;O5<H%^9<E#CIS@@D9]\YZ@<8'L:UC)/R?Y
MG/*-^EGWM^=K7^_S,HHN/D'S<$=>!D9^@(SUXY-19Y/(!!(.3D<=L9_7C./0
MUHO%D8CQR>>>1C!Z@Y/ Y'7O[U6*_,1C)&<C;R2&&3R!P021UZ#GDBK_ *[?
MD8RCT:]'^%_+\_(J,FXD@;21U!^\ 1SQG&.W7J>>]5Y$'*LGH WN2 & R,G)
MZYR,\D5<8%20PP>3QG'))QQCG/&#[8ZTAPP(8 ]B1R/KD9 ]<]O7(.-(SZ2W
MZ/\ !>ENYC*-NEU_6_Z&3(FW*L-R\<]NQ )('?&#^?0DP%".1R.P/WNO;.,C
MIP>>>>1SJM&0,#E.Y!YZCMR.N=W'W??-5GA'5#G'\/! YQDGJ.G0# (S@XK0
MPE"UVM5U5NGSO?[O,S"G&4(QZ'IT[8YR3V]S]*@9 V<95@><<9],]QQ^1SD'
M%:+(#T^5NN#_ "([=LD#/%0,@;Y6&&'O^/![CU';V/-7&;5KNZ_'?>^[MKYF
M,H7U6C[6Z_A;M^)G%>0C9! SN  R1D' (Y!Z^GTQBHW3'7!R.1UX!]./?'(!
M[U<=.,,>, ;O5><$GJ"2/FSQ@^^:AD4C@C*GC=QGG&3Z#&>XZ*3Z5HFGJG^:
M_P F82C?39KR^_M<HO'M&0..^0"0,\YP!D$=>O?)(Y$!4#)!''!7MVR0,]O3
MDDY]0*T2@ )#9P<$$YP>!C/;Z5"R \C@^W0^Q'0=N0,UI&=M'JN_9>??UOMZ
M'/.E9Z:?+1_);/\ $S&C#]!L8<GZ$GJ>V"&XQUR#C.16P0<$8&.I[GT QGU]
MN#6HZ9.&# \]L\\'MG(P>^<=/:H'C#?*X&<9!'0_CWY!.#VQ[ULGIW6__#/H
M<\H)MW5I+3_)NV_2WW%!@K<'\#Z'U!Z9'/\ D5$R$9!!=3Z#)_$<>_0<8YZU
M;:+:V.W\)Y[]L=!C..2#T SFHL^G/T(_QJDVOA=UH[=K]%_FM]S)IK?SMYV_
MKJ4BA'*<CKM[X_V3Q^1],"H2H8[@>3[G'3T['I5]DSRG4\X['/UZ=SQWZBH&
M56P<E2>.G)SZ@_S^O-:)IJZ^[L1*,9*TE?\ /Y,HNF3ROL#CGOR#D=.".#WZ
M5 01]X#((&[C!.-V,]1WSQ_,"K[IN^5Q@]01S^(/X'(/./SJ%U(/3*\$G'3D
MCIGKC\>U4CEG2<=M4[^J25WOOI?;7[RJ1D<\CNO&,>W /H>OK43*0,CH>B\D
M\]A[=^_<#M5ED*Y*] ,E>XQZ=<]^"?0"HP #G/;'/&/08/MW//U&,.,FO\N_
M_!\][&$HKI]RZ^2WU]>BW*S*KY(P6QP?0\X_7VJ)D*KRP &!P#GJ .2?S/IZ
MU;90<D85AP,=#QD#H#S^?I4>1G:>#W!]?KT/MZUJFG_D9VZ%0(IZJ"<9)]6[
MX''!Y.1Q4+(5P&(.1C@GD @$'/7J?3O5EE())'!)'!/0G(' ) XQQGC(XSD,
M/W< #C/7(P.Y&1R1_G' I];DO9^C_)GJW[27_);_ (D?]A+2_P#U&-#KZM\.
MJ/\ A'= 7TT+1Q]/^);;8_'!%?*7[27_ "6_XD?]A+3/_47T.OJ?PX[#P_H!
M/S#^PM%R,<_\@NTY'K]#^!]?QG)OCK^<*?X2DC^M>*_X."\ZU?\ "E#_ #.@
M5F7T(SSU&,GGUX[GTJ4%6S@YQP<$C_#/6H 0>0<T<J0PS[@=P1CIWZ#\L]>:
M]MQZQT?D?%D^!G!'?@_ATSG/KU_PIROMR&., !<@\A<\<=>W/OTJ-7#\$<X)
MP1QP<=^^"/SIQ7T QSQT_$<'_./04E+[,E]_X7+A-Q]/R]/7K^&I9R,X.3[C
M& 1SR<]L9(]*7W_SZ55W="Q+)W&03[<<=#COQ4R-\HVJ<<D#@ #<?UI.#6UV
M:+6\H]5L]N;365K.]DD[/:VY)0"1D \'J,9[ =?H*0'."#VY&>YQ_P#7I:@:
M>W1ZZ=?=W:WTZ][-7UN3*P./7TY_STI2 1@U""0<BG!SGGD?0?\ UJ#2,^CW
M[DAR.X[9X/3//?M3T?ITQSS_ )]Z;D>HIIXY&2,\@8[Y_'K[T]_)].B93CUC
MHUT[^19# ]#_ #I:K*_/'!Q[>WN<?C4P<$@<\_3_ !I I=):/_/;N/HHHH*"
MD(R,'O2T4 0LN/IVSBFU.0#UIC)Z8'KDG_Z]!E*#U:V[$.,=,]NY]L]3CI36
M&>0<'ONZ#&...Y'/6I*0CG(QGOVR,>N#[?E3WW^\%*^DOO[?U\]R'!'7W_''
M<>QZBDJ9L=P.A(Y[_I_GZ5"01V8C'4@#')&#^A_&BS$XO>.J[_G?8/3WZ_D3
M^'(%)QQ^8_#_ /72T?Y_S^5!%FK\MDWW^&_5NRO=]7?9+0K%2"-@;'&1CODY
MZX.,#@C(/KUH)P0#P<\@]0,$^_L<]N_>K!7)SGVP#UQZCTYX_&HG4$D!2"2,
M/T ''&1D^HZ'\JTYE+1[_KY!92;:O&2T:TNFU=*6^RMM?3J1XW#GID]O?@CT
M(XQ43+LYY*^O4CIU]CV]/ITF8%5Y(/\ #D')S@]>!CH>^?:C.<C!_'H?I_G_
M .NK.+NM5U_X/Z$OHIIK5I2TMI;OK=^FM^A "#TYHJ1D[K@$]1T!]^AP?P_E
M46><=#Z'KZ_R_F.#SBU)2V^XB4>5^71_Y^8UD#9(X;'!Z9/;/KC^51$$<$8Z
MX/8X]/YX/./7K5BD*AA@C(Z\TR2NRAA@^N?0@CTJ%D8?=.1P , GIW)QQ[U8
M*E><Y7U[CZ^W3G.<]>.0E--K5?\  ?J)I/=7_0HE%P2@.01P,X/(SP>"<'_)
M%1,@8G/##Z9&0",XZ@<?R/.:NL@&",*HY/7DGCT__7GM@&H67<0""IZYPN3P
M>,9)Z'N,<=>E6K2=X^[+MWMWMT[V?;L92BX^:[]EY^92(P<-P><=1GDC((Z9
M]#SS[C+2,C#C/?G&!^1[<_X5;=<?*^"#G'/7!'7I@\CIGO4!0KTRPZ?[7?KT
M!&._7/:J4M;-6?2_6V]O)>?=&4H)ZK1_GVO_ ,#H5F4J3_<]3@C!XP2??Z\'
MG@5"T?&4SSV/H0>S8Q@XX.,#-6\#K_#QQGCGCIC'7D\_K3613]S:#G)P<9!!
M],]R#TZBK3:V=KF3T=GO_6WD4&48)P<]Q[].<Y_$^G//4PLN[AACN"#^>TC\
MC]:O,FXYSM(&#ZY]"#Z=C[GM43* <,!GL>Q^AZ]\8_GUJU:6M[2_-_BVG9)D
M2@GMI\M&9Y4C[WS*<<X P22,$9Z@XY'0GM4+(5Z<KW!Z@8Z\_>'!SZ9 QSSH
M.F!@\KT.?3W]^Y_$]J@:,Y^7 'H3C!QCC@]><Y'TIJ5M)V3OIO9^F[OW]48R
MCT:_KR,]D(P5R0>V>1SQC/&.Q&>!T[U"R9)(^5NX(./Q'K[CTQ5]DR3M&",9
M!.!UST&<'.>W8=0>(60-U!5L<'H1R<9[$9SD<_G6B;6SL92BUYKO_F42"05/
M!*D8/;(_7KV_'!JLT;#C&0>>%!&>G0GV_6M%US\K#!['MG_9/'(SZ#GUQ4+*
M4ZG()Z^G'?TSVQ^0J[J36ZEY;7Z:ZOL3OH]5V9GLA7Y>"-N2."5 QPP.,\<G
M SU [5 4(Y7D''RXQST./3U(/3!YYK0DC).Y222>@('&,9SWZ#BH9(PI!&0S
M?P]CT+$G/).>,#KQR*I2:TEITOTT^=]?0QG3OMJOQ7?LK=%K?N9S1@@[,#U&
M./7[IX!Z=>U5F5CGJ'],#CIRQ.>H P >^,8!QIL@)YRC_ADCG\".OY9J!E[,
M #V;MGV)],]#W]:VC/9/;O\ YG-*.FJ37X7_  ,IT*\. 0V3GJ,YR0<9Q@GJ
M<?H:@:, $Y8G!VC)ZXX&/XLG]..@K4="OWLLIX'3/?[Q.,#&, $Y.?7%5WB"
M D#)(V@XZ'''L!D9^I/:KNGKN8RA;5:KMU2UOY67Y=V9W.<8./[N!C!'()Z9
MZY'KP>>!&R _<!##/!!P!QG&1@G(!'.#R0>]6RBDDE><\XSR><C ^]@]\=<X
MX&3$>"0<K@D@''W<G'J" /RQ]*M2:\UM;RUV\S%P3NUOTM_7^12>-#D8(;UP
M>&Z?,V".O;OGC.151TQ\KCZ-^ .01G!Y'?KTSTK5(5^",'MG@^Q'K@@8]Q4#
MIC*D$YR 2!CV).,\<8'KQTYK5-/9WMN82A?R?];^9E,I&002O8@9QDG&>^1@
M<XZXSSU@9" <?,OIU(&.>O!''3WQ[5I/"RX(^8<#&3N]SR.G ZD9/'.>:Y3N
MG3KM[8Q_#Z'V[Y.2.*I2:V^:?7]=#"4=6FM>_72]OE^AFE,@F/CU&.O^[GCG
MDY'![&HM@+?,,-SG .2 <#)Y'(P=O49'I6@R!NF58=1T_ \<=#@CCKUYJNZ'
MH0-V2 QSTR<=N<@ 'D'/([9UC-.R;U[?Y>7S[F,HVWLT_NO\^MBDR@XW<=0,
M\'/&<=^_/X>E5F3&006';.3@\X&,^@Z^A[9Q5]E(^4@_= #Y!&6R!U /4CD#
MJ><  TS8R@DD']*M2<=METZ?\/\ J83IIW>_;NK]NFFYFLF,YY3H0>2.G)/?
MKVZ<9Z$BJ\0.2@Y[J1S[$!MO'49SCZX-:C1 <J![J0/3MQG/L>.O(JNZ9/!"
MG)!.<9 / .0<$9XX.<D^AK:,KZIM-?><TH66MFN_Y7O;\-+F;G! [GI[_CT_
MSCK3&4-QG##H1U'U'<=#@U>>/<2N N,'/<D9Z#^[SUP#SCU%5C&0V#@=2.>.
M?3@$G!YXQG.*M6U=[-:KMZ+?7UT,7!K:[7XW_!6*C+@8?H>XZ?\ UB#CKWZ>
M@A9"N>Z_J !DG/L1]>>/2KYXR#S^!/3\*B,>.5Z==OMC^$^I/;IR>E7&6MGH
M]+?UY_U8@SRG]WIV'_UR>GI4+H">X/3(/H<<CO@_AU^AO&,'E?E/]T]/QQD@
MX.?RR.*B9<_*3M(/U_GU![''Y<BK,)T4]8Z/L]OR_KH9Y'3((/!_+GH,\\?[
MV/:D*@\G&#QD@@CCL3T&1GIU.>IJVR=BI8'GV'//H??O[>E0,K+T&1GC!Y'L
M<_D#DD\9YIW.64.ZMI_7E_78K$%>3DKU!ZX!S@'OVST/7G%,==PSSD XP>_]
M>0*L9  SC;T!Z_3(QQQG/^<QLHZJ-NT$L#P2.O'7/0CG'7K6BEW^_I_P_?S9
MBTUZ?U;_ (/F>D_M)''QO^)'_83TL?GX8T(5]2^'<?\ "/: ,@D:'H^?PTZV
M'3]/;I7RU^TE_P EO^(__84TK_U&="KZ?\//CP_H)7D_V%I';H3IMJV/\*_'
M,F^/$?X*?_I<C^L>+'RTL#V=:OZ_PH=#?'!!'&.W0$>A'3\<<<>F*E60'@\'
M&<'I^![]?3U]#5<,.=I+ =><X].O;KTR?K3R >M>\?&)IJZ)R,_XC@T\.R]1
MD< 8[=N?KQZX]:KARO#9(_O=Q]?4#U'0=N.900PR.0?_ -5)I/<9.1GD,.PZ
M ].?ZTF#TR0<]>0#QGUQGZ>GUJ($J<CIR2O3)(Q]/0]N_-2!@^ 3AN3@<$8R
M/?M4^]'?6*T\TN^@TVG=?U\MOO)D?J,#*@#KUQNR>G4X]^O6I2P!P>2>WUXS
M^'7WQ54KT^\1SW&>WK3][=. #@DA2,<\G.3@XYY!^E#2EJOG^GH:J49))Z/?
MT:M;6ZOT:779IJQ8HIBD;1R6Y)'.2>2/\^F/:GCD9]:S::*UNDT]4K-+=];I
M*T5IH[VN[6%#$ CKGN2<C@#I@YZ9ZBI0P/H#Z9YJ'_/^?RI0<'-(J,K=;I^=
M_FGK^9,0.<<'U'!_3K2;B".G)XP3_AVIH?GG 'X__7J2F:>[+Y?>B16['N2<
MD_Y_R:?D'H0?QJMT] ">?;CUZ#H.W4T]6P>"#Q]?Y46^[^MQ7<=&KKOV7R)Z
M*;N7U_0BG4BDT]G<****!C2H((&!GOCWJ(@@^WKBIZ0@$8-!,HI[;]""F;2!
MP?PQU_4]?:IRG3&3ZY(_^M4=-.W_  49^]'3_@HB9<\CJ> .G0?IP,]/2F<]
MQCJ/R.#CUJ8CJ>3TX[=L\'CH.](PR.01C.!QR<=.,^E%NW]?UW^8[*6JT?;S
M^?Z(BH(!X-!X."5.1D8/7DCU]J*1#7>ZZKR:V?2]NSNNC&XR!Z _7@9%5]NS
M&#NR.< _+T],^I].E6J;M&1@@>H YQQW]^W<8JXRMH]OR$W?26J=K2\_/91U
MMRZZMM+L09_GWXQU]?4\?6@JK>A]^,CN,9[C/_ZQ3I%&>I+ # X.1DYR._&>
MXIG*CD8ZXR !GD@=>/\ /--Q4M8OY>?Z"UC97YH[;*Z??17V\^O<B(*\$YST
M.,9Z=>N.N.V:2ISALCKV/\OI_G-1&/;RN2"<D#''TZ<=/?CZTU+I*Z?IO^1+
MBFFXOY-6];W;:>FBZ^0VHVC!.5.T]^ 1CCMQZ#]?6I 0>E%69E;U!ZCJ/H>W
MJ,TC*&&#U[$=1^-6&4,,'/!R"#@C_P#7T-0D,N-W(_O#H3Z'T/Z']* *SJR_
MP[P!U[GCL,'DX[G&<<Y(J)H\ E6. ,[2,Y(&<9SD9&.*O5 8RI 0<9R<^_
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M\J4C/<CZ?Y]JKX!_Q'7\_P#(J19.S]>F['!R>.G3MUP*"B=),85N,  '!QD
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MUDWV/YEPN!P^.P.)5*,EF.&_?)<[:Q&'3;E&$&K*I%)Q]W=\FWM#_1;*,O\
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M.?H3T/?T)Z]ZE5\D8)5ATS@\?R/&,_AGD5G*#5VM5^/W>7KL,O*_;/(( 7U
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MJOC#6;CRT,GEV.E:%I-W=74SKE4AC7=))A$P6%?Q)?\ !2']I3QA_P %^_\
M@I/\)?AA^Q]\/_%DW@G1=+L?A/\ #*?Q%IYBOVT>ZU^34O'OQG\:VEB9U\(>
M#X4E@U!K.]GN+^UT/1K9KC9KVKQZ#:?U+Z%_P:V?\$H=(O5N]0\*?''Q3;ID
M-I>M?&36+2SEXQAYO#FGZ#J*X)SB.\3(&-PSQ^P'[,/[$?[)_P"QCX>G\,?L
MQ_ GP)\([6]MX8-8U70M,%QXL\0K J)$WB/QAJLNH>)]==1&C;M2U2X&X#
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M35+3PQ8ZCX@DDD\5^,CI\!N9-!TRUMS+/(+.WN6O(KN"UYK5?^"@GP_D\%?
M[QCX$^&7Q+^),_QX\4>*/ WA[P1H<.AZ=XYT'QSX3BNDU/PKXCTG5+X6EM?V
M^I6CV%U<)J)M+>,?VJDUW8O$!FVGPI_:L_9_^,7QN\4_L_\ A/X/_%/P'\?O
M%&F?$&XLOB!XYUSP-K7P[\?P:0NF:O/?&RT;4H_$?A'4K@+>K%H^_6D4"V2V
MMU@-S>\U\.OV+OB5\/;[]E'4+OQ'X8\3ZO\ #CXQ_%KXQ_&K5;>XO-)L)-9^
M*6DZA'<6'@;3I]/:XU'3M+O;R&P@DU!M,GN[6T?4I8H7N6M8->;$2DTE)/FD
MG^[BHP7MH*#IRO\ O/W7-*3E=:.346E&6"IY>HJ3=*4>6,HI8BI[2K+ZM6E5
MC7A"-J+CB8TX14%%ROR+F4G./H^G_MP^'=*\/?'R\^+OPH\?_"#QM^SAX8T#
MQEX]^'=[>^&_&%]J?ASQ5:7%WX<U'P?X@T.]MM%UI=1:W:TE6Y.G0VL\D!EN
M#&3(O5?!S]J'Q!\2_%_AWPIXG_9_^(7PUMO&GA2^\8^#/&?_  D?@OXD>"=3
MTRR2VG:P\0Z[X%U&[B\$^(9K*\M[JTT?78W>XQ+:R7D-X;.*_P#._'/[-_QJ
MU7X[?M6?%+P/J?PTTZ#XO? KX=?#_P"'\GC:QC\6Z9-XB\)P(FM:;XX\(7VC
MW5D/#.K1QRZ<;Q)-1N8X;D7D%@]Q%'"?)?V??V1_B]X,^/GP[^)MK\,?AI^R
MWX+\*:'XKM_B;X0^%7Q9\2^-=$^-.MZYI$5AIDD7@5M-L?"GA/1]-U7[1XB2
M[N))-=CD$&GM#,I@N=/?M,3&<(M3E%3E%M0BN:*J-*3;O'^&TW;D:2YHN;;@
MI]GE\Z-62=*%1T83A%UYMTZKP\9RI1@^6K*U?F@I-5U=\E10BE5?VG^T9^T-
MX?\ V=?#'A76M5\.ZWXOUSQ]X[\/_#;P-X4T.[TK29M<\6^(WE^PP7OB#7KB
MTT3P]I<,5O/+?:MJ,_EPA8D$+AV(^<_BI^U#J>H?L[?M':QXS^&WQ\_9^\0_
M"GP[H%]JE_X.\2^";G6+BTUW5M,AL]1^$?Q;MK'Q+X$UJZ#O+;Z@9M+N?(M)
M'1K8^:EQ'[5^UM\,OB5\4OA[H^@?#_PS\(_B!:6OBW3-4\<_"OXS:=')X:^(
M_A"V207NAZ7XG_L_4;OP5XG1G5M)UZRBM3^^N;6[O[6SDF$GP5;?L,?':Z^$
M'[6/A#1-(\(?"+0_C5X$\(^&/AG\ +?XM^(_B#X-\)Z_HGB*UU;6O$]_XIU+
M1EL- .K6<$5E:Z5X8T^ZLXH[8//(I=H4=>=?GG&G&4H.E)148Z<WLJCUG?6\
MU!*THS3:7*TW*,X2E@U2I3K3I0JQQ%-RE*JV^18FA%KV:5HI474FW*G5IR47
M)U(22I2^K];_ &N]3T+X@V7P0\!_ OXI_&OQY9?!/X=_%E[C2M?\(Z5!-X=\
M4V%V#-XEUW7'L;&RUU6T[YEM[.X;Q%JUVUMI5A;E"3YAI_\ P4IT+6/!>E?%
M_3OV>?BZ/@3'XDTCP7XX^*FJ:IX.TA/!7BS4[FSL;[3(?"DFH76K^*M,\/WU
M];0:SK>GSV%M$#(UK;W$JQV\OOOPJ^"/CCP;^TMXK^+6LG0CX4UK]E_X$?""
MR6RU*6YU<>+_ (<7VNS^(FGL&LX5BT=HM0MUT[45N9)[MC*K65NH4R?-FH_L
M;_&"Y_X)^77[,T+>#!\3)_'FN>)O,;7IX_#+V6H?%O4_&MNTFLC21<-=G0+J
MV1XSIK%+R-K0S^5$D@4GBTI.+>D:[C'V<-73=/V4;MM_O$Y]VU%6<6GS$8Y:
M_9QG"#<I82,ZGUBLFO:K$?6:G+%<B=%QH<MH\L7)N<:D9<L?9?$7[86NQ?&C
MXK_ [X:_LV_%+XO>*/A"O@^\\1ZGX7U[PGH^@SZ3XM\*:=XI@NX;OQ!/:E-8
M$&I6^GZ9X;5+B^U^ZBNYK.:VCMI8UX2\_:5/Q:^(O["7B;X6>(?%&@^"/BK\
M0_B+H/CKP?J2G2[Z2^\,>&]3M]2\(>-]+BDN(GOO#'B*QN()XHKN[LFO+=+J
MQN;NQ>&1_*?!_B/]H[P]^W+^W9:_ ?P3\+_'T$A_9S_X2?2O'_C74O!D^DZS
M;_!K3(/#6NV-]8Z/J<>HZ+:BXU>/7-*Q!J5W')8R::6E1EC].^'/[''Q!^'^
MM?LG:M=:[X9\0ZG\./B[\6/C#\;-5M;F]TVTN?$/Q2LKZ>ZM/!&G75C)-J&G
M:7?W<&EVOVU]/GFL[0ZA+%'-<O;HU4KU+J]2456G&2Y(QC&-/%0C'V<T^:?[
MM34[WTBVTG\3E0P=!1<E1C)X6$H?O74G4E7RZM.;JTI1E&E:K*C["UO>DE%N
M_/3^9?BI^T!\7M6^ WPYT[X17?Q^U*V^(?[5GB7X::W\1]6^*'PWL/B/YFG>
M/_$>FO\ "OPYJITK14T:QUE=+CB\+:S-I<FG:#H$"Z=X@U.>[DW2_17@C]H'
MP9\ =#_:7OOB+XE^.VK:;\#M3^%OAB_T/XC>+?#OQ%U.'Q)XF\/Q+H_A3X?7
M&BZ?IDMSJ&L:I.EGK%UJNL:C;W>HB355OK33()'K.T/]D'XNZ9\)/A%X*NI/
M!_\ ;7@?]MC5?V@-:,>NW1L6\ W?C'Q5KD$=C<-I0:?Q ;#6K,/I;Q0PK<+/
M$M\XB\QSXQ_L1>.OBW:?MAVDNJ^$M,;XO?%/X3_%'X2W&H7FHWNG2:A\-M)E
MM9M,\=V5I81W.GZ;K'VB]TJ5=.EU&>*&]BU2..62T%LRBL5%^TC&<IJG%1C*
M[C&2P]5M)<^[J<JO+FO)I-WLQSEETTJ%2=*%%UIRG4IV]I.+QF$CS.3HO_F'
M]HXNGR*$%.48Z2C/UGP%^V%/JWQ(\$_#'XN_ _QQ\!]9^*=IJUW\,-2\3>)_
M"?BS0O$\VB:7_;=_H6H7GAV5)/#/BI--#7 T+48+AO.6.R>]6^NK*WG^</VB
MOVX?%>J_L\_&'QO\'/A)\9-,\ 0Z;J^@>"_VE]'O/#UAID/B"SU*#3(?$FF^
M'GO%\4P>$)]45M*M/%JQ26\MW- HLC#+YJ=-\(_V4_'TGQ@^'OC7QA^SG^SC
M\"O#?P^@US4M6NO _BC6?BCXO\9^++_3)M.TN?P=<Z_$Z?#_ $*PDFDO)[B:
M<ZY=0-_9\D<T<GF:=Q?B3]FS]LW1?V:/$W[%W@+0_@=KGPT_LG5_#G@[XN:W
MXXUW1?$,7@*ZUM]<M/#&M>#5T#4?*\7^9.^G/K4-QJ.@"P,]\\HU#[/;Q5*>
M+E2FKU=8UE%QHIU7+DBH1E&3@XQ<I5%SJ,6FHVDN53EC&CED,32E%8>\:F&E
M5IU<7+ZO"FJ]7VU2G*,:JJ58TX4&Z$IU(N,Y24)>TE2I_J'X-GN;[P;X-OKR
MX>YOK[PAX6O+VZF8O-=WEWH.GW-U=3,3N>:XN)9)9'))=W9B6)S6^RYX(VD\
M@'G\1VR/\<@@YKS/PS!\4='U_P (>%[O0_!C?#/2?AAHEAJ7B*'6]3D\9)X]
MTFQT[3VTVVT;[(FES^&7M[>YD&J2SI?/<)&OD+&^$]592>''?@C/7!Y!/?'0
M^QS@\5ZM*;Y4G%Z))\RM>2C&[5[WCKO97?-IW^>JQ2G+6$E)RDE%J5E*=2T9
M62Y9))7CO%..R:2HD=F ((!Y'!'T.>A[<XXYJ!TV\XRO/&.0,<_5?;_ 5?*[
M>>JD9W ?^A8^HQ^.>AJ)E()P"1GICM@<YSZYXY/?I6B5O>B[I[Q_-J[OIKI9
M7V['/*#6VOE;^OF9Y3C*<CT_'M^O!]AQ4!0$DK@,.#Q@=><CUZ\_KUK0:/)S
M]UN_'WNF"1V_#UZU"R@G!X8=_8$].F0><9'?/'%6I)[=-UL_N,I03\OE_P ,
M9S*K'####'L1[9QR.>G?TJ%ACY7Y!/'HV,'UR,$C.>/KS6@Z\8?ZAATSVQWS
MWQC\Q4#*5R#RISS[<9W=AR<#^F,U:DUINK[?Y7O;[C)IK1E-HPRA5P!_,8/'
M'7.<^YZYJJ4SR@YXRGL1D$8S@#N?4\UH%"O097C '4<XP!W XY)SWYJ QHWW
M>,=<#.<X(ZU:[Q?_ &[W[[NZ^2)E%26N_1_UO\]NA09 <E?E;OZ=3G<!WSGG
MU'7%5W0-P04;'7H<8/&1@XR,XSSCIBM&1%! [X!W=^IZ#IC"@8_3FH&7. 2,
M=B,CDY QGN,'CH1^55&79V?;S].OW'-.G:]EYWUL_P!%Z7T]&C-D0$;6 '3&
M.C8[#VQC@D<X';-5GB*LH ^4]#CA<@@]SS_$.2>% R "-5UQPWS+Z\C'(QG&
M,9)X(]#Z&H&5AROS*?3DC/3ZCISDGJ3ZUNI)Z;/^OO,)0[K76S_K>VGY&2\9
M!;:<D')!SD\ X!Y[<<\=.G),9!7;SU!R,< _+P ,>N!U_6K[QK_ <'TZ@C\3
MDGTP23CN, 5V49(88<=\'/&<$ _3(Z\8JC"4>C6G?];ZI7_X#*CQ[^?N].G4
MG(.21Z8^4_7BJS)N&V11GKG@$]<8!Q@ $YQWR0<Y-7"I!Z$D8 (Z=,X'..G4
MG.>1GI2$ \..,]^"#C/.,#IT(/<=ZT4[Z/[_ #_KJ8RA;S7]?U=&6Z%0<C<@
M(&3R.3TY')4X![Y!SR*@*$?=Y&.F>?P/<>@_7%:K*RC*C<N.,#YL8S@ <=AC
M QTXJJT0R=GJ<CC!/!],Y.3]W./EX((SH82AU6W;?_._Z>AF,BGYDZCL.!VR
M,<<X]<\X(QUJN5R26(5\D#Z<?>[_ %/&<+V K2*ALD'#=>G/3@,/R'KQP>:@
M902,\,!CZC/4>JG!Q]<^E5&;5^O;7KZN_H8RA?96=]O/MKM_2*![AAM.._IZ
MY],G%0L.H(R..<$J?3DC'7]>.M7F3HKC(XP>V1G'/'/H#[]:A*%#T!7GY@ #
MTR<XZ=\GICWZZIIJZ,)1OY/O9K\'8H-&1RO//?KT/!QU'3KWY/M690?F0X/&
M%&0.V0!]WGUQP2#G.*T6Y/R_,2>GW?U/7Z5"Z!P=IY((/OD8&?3&*TC.RM+[
M^WJNMN]SGE2U;V[V5UY=DG^I/^TE_P EO^)'_82TS_U%]#KVW0V:/1M%(&0=
M'TO(XXS86Q.,]CCIG@G([Y\2_:2/_%[_ (D>^IZ4/^^O#.A#^M>UZ(P;1=&P
M>FD:6#]186X_F#S['N#7YKP__%Q7_7JC_P"G:A_0/&[2H9;?_G_B?_3%(W5D
M#Y(//("XY&<@C/J0">0-O7GK4HQNY)&!DXR/E.[ .,CJ ".G&>I-4!D'*G!]
M1W]CZC]?0BIEE!&).HZ'USV'.?P//IG!-?2N*?KW/S]-/5&@LBL0AR /ND9&
M< $=.VTD\]>HST$P8 D+EL  G(P/3D_CGKR.>>M#(X). Q 'KT^4>W'8>@ST
M.9!(5 X(P "01R0..O4=??I[UDTXNS^7GWMZ%J3BTT]OU+ROMX7D'^$Y'4=B
M1P,#@?7%3JP;I^(/!'U'OVJHN&7*C&.%.>,=>/;D]O:GAB#C.&'4CH<\@'_#
MV.#S2.BG5YG9Z/I_D6N0<@X(_P \COU_"GA^@8'K@GL>PXS\O/.<<$=>:A5\
MG!&#V]#UZ>G'8GUQG%/I.*EO]ZW-BUO(^]S[CC'U'?Z].22,"IE9L#D$#I@=
MAP#GOD?SJBK;>"?E]3_#Z?AVYYS]:F1L<KRO/ /'U'H<X]L9XR:QE%J]]OYO
MROMKMTL!>#9!(' ZYZ],^_8^M.(SZCT(."*JJ^3P3G@LF?H"#QZ<>AX/0YJ5
M7R0 ,9)QWQ@<\#Z'H>II&L9WWLBPLF.'/?@XP,>_/!S^'3WJ6JP(.0<=P1^G
MX9IP=P>?F7T_B^N< ?\ UO>@LG#%.@RN2=H'//O]<=NE2J0X!/!ZXSR.W;'4
M?SJ%6##(_'U!]#[CO1R.5.#SV!'/)ZCN?K4RC?5:/O\ \-U GYX]0,C!X)&.
MO [XIX<@$/G)/50>F !@]CD8Z5$KAC@K@]LX.<Y].!T_SQ3B /3'&1T[]<YX
M]^.U+FO[LEK^%^A49M:;K].MNW?UU)T;..#CG!..<''3KGGG/<'ZEXS@9Z\?
MG596V]#E<8 !'!//4Y'.#UJ16)W%1@C!/.3GGD8XS^7TYI2ANU_P?/Y&MKI.
M-EOI9\K;WO;=Z]U[VMVB6E!(Z4T$-R""*6LQI[=';FMU2O;I=:/3<F#C R><
M<\'K^5.JO3P^!@Y)) '?J0/6@TC/H_O).1],G/'/.3_/VIX<X&#QCC@=/RI@
M[^QQ^@/]:0@X^4_@<8Q^1/\ .G^?YE.-]8NU^JZ_<600>G]:6JX8\XR,'IGZ
M>AJ56Z YS_G_ #WI"4M;/1_A<?11106%(0#UI:* (2K#/'3W%-JQ43C W<8&
M.!QU./IW]:#-P[?<1XYR/QY.#Q^/MVIA3(&" 1D=.O0<X([CKC\!3P<C-&!Z
M#\A3OT8E*VDE>WE>Q"01UI*D8?PGT^\, XYZ9/7/.<TS;@9SD9XR03^)'!Y!
M_E0U;T[B<;:K5;W$_G_G/]*:RDYP>JD$ =>#_CVIU'/;_([_ )BA-ID;7MUM
MH]O.RTLY=[VOJ[$)3C*Y!XQN)ZDC.1COSW]ZC!(.TY&.V.,C@X.><9_^OUS9
M;D8R1D]1U&.>X/I4>Q<_,HZGYB1R?4^Y[^_85HFI:22\A-*6RM)+FTW5]-;7
M\T[/?8C(# @]C^/3L?H<?G411ATY'/U [=^3Z]SCCDXIY!4@$YS@Y! ZG'U.
M,=1S3Z5I1NUJNWZO8.MII:W2=K?FV[W]/3J5Z#^7N.H(Z'\#4C1\Y7@]QV[Y
MX'?IS[5'['@]QW%4I)V[OH9RBUZ=_4Q[;P]H-CJ6JZWI^AZ+8:YKQLVUW6[+
M2-.L]8UPZ? +73_[:U2VMHK_ %;[!:@6MB=0N+@VEL!!;^7$ @T#D$!N">1S
MD?GQS[58H(!&#R#5?U][N_O;;?FR6V]VWHEJ[Z)62UOHEHELEHK+0K%0V,\X
M_GZ_45$Z$'( V]2.2?R].A]CDGBIV0KDCE<_B!W)]0/IG'?BDIIM.Z^[HQ-)
M[K_->A29,_,G4GD9P,8QTQUR!4!0'J2&&1G\@>OWAP.?4YXSBK[19QM.W'8=
M.O?O414,2&&2O&3Z]#Q[XS5JSUCI)+731^O?6]M='N92BXZ[KOV[7V]-.I08
M8.&R,\ @D ]?3@'V/3/4TU@,88$C(Q@G(/;]<\Y[XZ5:9<?*V""!S@X//?WR
M/7G-0LA7IEAZ$\_KUQV'4DCT%-2V4M)?GYJU[+IKU,I03NUH][]WY^1692I!
MY(YQZ\]F')./7UQ413NF"#VS@#W![?3'TQ5L#H01WQP>AYQU'M^5,*;L,I )
MZCJ.G<#OTYX]ZT3L[HR::W5OUMVU,\J&R1C.>I^\.>_/3CI@';QUJ)@"2K @
MX!S_ ('\2/S'K5YQD@%=K?PGC(/)''H<'/XBHBN#AE'H&QP<\X&?H>/;W%7I
M+:\96W6EW\MUU(E!/;1_UN4'3'7E<]3SU[-Z>F[/IGO4)0KTRP^G(_Q_+/'?
M-7V7&0>0<_7!'<=QR1D5 8\_=^4CL3D?AUP/3KUZ<"J4K:2W[VT=^V_H[]?(
MQ<>C6O\ 6S*!CQ]PY']TG^1SQCTQVJ H#RORGN"/T(XYZ<_S%:!0')7@YY';
M.><CL??^E0-'GJ-K]<^N,<$]".1G']#5IV=T92BUKNB@RY^5A@\$$8/ /8_4
M<_7WJ-HOE('S$\$GCC!Z8Z'I^5773D!\'^Z1D<GJ![\ _P#ZJA*E>N2.N[T^
MOI]>F/H:M-2[*5[II?\ #ON3^)GE>I&67OD8(SDC _B'![<8)YJ$IU*>IRIX
MYSSCT^A'Y5?,1'W6(]=V#],<<=ZA>,@XS\QP<_PXYX([\*>F.W/%5S-.ST[-
M:?YN]S&=--76R^]+=Z[6Z][&:R \I\K#C'3 /)XZ9.!ST..O>H'CR2I'S<%F
M],8*\< YZ=< =S@UI,A)Y&U@.N0>.< ^JGG..0:@=,G:X^C#\"<9S@],Y[<U
MK&71[=SFE'?2Z^]&2R,K <\CCH>HX+8 P WMP <]<5#)&P9B.><G'!'RC&/4
MXQCH<\9.2*UF7!&X @'AL<#(/7MGCZ<^U5'B8$LISG)(.3G&,$8'''!_#BM-
M_3N8RA976W6^_KTTV[E+! 7/\0R.N1C'7U//M4+1[@=N5)X(.0.G8= >@ST'
M:K3*6]59>.N5R" W ZY())QU[G J%@02I)!QQ@@*1ZG)SZYP#C&/>KC)KNUV
MO]UC&4$]K?YE%X\\,-K@D;@,#C)'3).5QQT[D<56=,95^Q'(^N5.1T[9[9.*
MU64/U'/9QCMGIR?4C\3R,U Z!00RY49RQ[CW[D]<C/./0BM4TU=?/U[&$H)]
M+/\ K5Z&6R$=1N7UQD_BO/XD>O057,>/F0Y']WD\=\=23Z=.F.:TGC9#QDCD
MX/48]\X P>Y.2",BJ[)U9<@\Y4G@GN.>ASWZ9]JI-K9OII?33N82BGH]UVW_
M %T,XJ"05&#@X!X!4XSCJ!SM/_ZS414-G (('T'(SS].]7F3><XPPXZD8&.0
M<$'.>_LI[5 R9X;Y6'.1@<#'7J"#P>#C/';G6,D_)V^_37[K&,HV=GL]O\O5
M::V]"K^TE_R7#XD>VIZ6?R\,:$<?CTKV'16SI&D;3M*Z5IH!/5O]"AXQT/3)
M'../>O'OVDL?\+O^)&3C_B9:7^?_  C&A8'XG KUC1F!TC20V5 TS3L>Y^R0
M]2.!CMG&2>.0#7YYP['FJXO6W[JC_P"G9_YG[EQW+EH98^CKXJ__ ((I;=WY
M'1+)V88)/!S\I_'C![8/X5)5%7)X<8'.3QQP/0GC.>>O3CBID?:,@[E].IZ#
MIC\.,8&2>*^F::=F?GL96V::ZV>GX%M'*'G++Z=2.<Y]SUP>O0'CD6D?=\P(
M  !!R,@'.=PY Z'KZ>HXH@@C(Z?B/T/-*,@Y4X.<X/(R.1QVY[CU.<U+2>C-
M5)/U[&@F0P .,^F>!@D'&01G&,\$DM[5.'!^0NJD?Q @$D=0<]SN)."><CKF
MJ"2*^=_RL.WJ.H)ZCU'UXQR!4O'!Y/8<=<+QC'L.#QDC(X/.<H-7:U7;KZ+>
MY2=M47^5X)9L@9P#D>_!. >?3IQP*E5]O'!7GH02.YXSD\\^O/&<8JBLI4
MYR,L<9^;'KW!/&5R._3FK*A2 RDGT[=N_ (S[]CZ&H-H57'1ZKOVN]7Y_P#
M+8(/0@_0Y_E2@D'<,9Z<]"/\@'/7C'2JRM@X&%/=>Q_^O[CG'KCB97#<$8/8
M'O\ B./7C.>,XQ0=*::NG=$X=20#PW4=AG(Z$\'G! _,5,'[,<>C=!G!X.3\
MH  '!Z<#TJJ1FGJ2?E8YST/T'0^^,D'U'T!SE"RO'INM7]V[OTLMQEY78 #
MPO Z]AMY[?D3[9%3;AZY^G./KCI^/O5$,5XY*^G<=.AR.,#&.N?6IE;N#D'
M;CD@$@\=0>3VY[5GK?\ 1II_U_2*C)K3=?D6>0<@X/Z'ZCH?Y^]2JX/#8!^O
M!^F>_MUJL'&<#)ST!R.>2>6]A]/UI_4<C!'Z'U!_&@U33V?^98(!_P#UD?RI
MP<I@'&W.,]QQT]#C&!GZ>]0*[ _-R/4#I^ R3GVZ5*"&&>H/-)I-6&3\. >W
M4=/<=\C_ #FDV@\=#R.!C(SWXY[9QZU$"RG(YX( .>F<_3CH.!P>M2AE;O@@
M<]5Z_7&>GO4*\-]8_E_PX)M.ZW_I$ROD')5"3W..P['&<]_S&:>"#CG)&3D=
M".1U''?^E5B.>1D''.>0<^_.#Q^M/1BIP>% (4X).202,#GU_*FTI*ZW_K1]
MC924]&DFG=?IK>[>KTL]-==2QSGVYY]^,?GS^5%1AAS@L1P2,$8//.#CCKCK
MCG/:GY'K[>M9M-:-?\$>J;OJM6I?BT]$E:Z2[I-NS3'*=I!ZX]_ZG-3!A@<@
M?B*@HI%J379K^M;HGP/?\"1_(TGW< XQD\Y]<GG^76FA^.>N0 !GG/ Y^IIX
MY!R/J.OO3_%?U_78TTDOZNO.Q('P ,9]\_\ ZZER#T(-53N XY[ 8&?Q)8#_
M #TIZMC./;J"/7Z4?B*[COJNZZ6V^\GHIBMG@]?QI](I-/5!1110,:5R,=.<
M]/K46T^A_(U/103**>NS*])T.>>3R,9[=>!GL*D*'L.,>HZ\TT@@X-!G[T7^
M'E_7H0%#P5 )YR<XSTY.1USGZ<TW!'48J? ]_P S_C4;<]00V !P2.O4X&!W
MXSVI[[?Y#:4E[N^[7?O]PRCVQ^/T[?CG]*7:P!)' [],_@>1SQ^O2DI$-;7N
MFM4[:IVM=)Z;::W7S&,"<],%2#Z@<YQ^!J(KA<JQ;T^4X.6P><9/7MZ?6K%-
M()!Q@'(P3TXP?YYJXRMH]OT_7YB=FVI+3=/6UDM>9NR33;LKZK6Y7&>!QP.1
MWZ#@CM@YS^5#*&!'?U[@X(!_GBI @)Z-N).X@D#KR0?KV^OI46&&-W&[&#P>
M ?;IU')]?I5.*>L;7W_745G%>[9QWM?57WM:]]'=7=]->I$P92,\K@Y;!XZ]
M>P[458J)D(Y4$Y/0D<=>03^ Q0I-.TM//^M+$N*:O'[OZOKY#*C9,\KP>X['
M_ ^_<XS4E%69[;E?\P>N",'\C_/I360-P>G?W[#/TY_R*L,JMU'/8]"/H14+
M IU'R]FS]2 1UZ<9[GZT 5G3&%(RF!D\@#'0>V,#J><XJ%D P5R1GH!D#CJ,
M9/4#VS[XJ_4+1L/N< =!U)[G&>W/?G(ZX-6I)JT]5WU_';\#-P_E^YOUUN[N
M^VFQ0*9)((#=_0].HXP>I]<\$U$5^;YAAACT/'4$$CU/4=_I5XJ&(W A@#G&
M1ST89'!P1ZFH2N?E< ' QR,]QD$=\YX[4[N/]Z/=;KUMHDMN]E=F32>C7RU7
M^3_S*S $$,<<C#$?0]<8Z\5$5(XQD8X(4D%2"!T& <=1TQTX-6&5EZ\KW(X(
MY&">?Y=,&FY8?PYZ\Y'3M^E:)I[-/T,I1<7HFUTLFVO)VO\ )]2D5*],LI].
M2/P'4=.>3GK4+(220>O3N/;I^ R,^IZ8J^4. 4&0?X2<8^A/\ORJ HISM&UN
MO0@'/7/8]QP>#Z&J35K2U73^E;[R&DUJ4616/HP[CJ,'GC\3G/K4+I_"PR,\
M$C@Y'Y9Y/'.<'C!XOD9^5AM/7&0>.F<]/7CK4+KU4C@\ \<Y!^N.^">O.*J[
MCJKRA;U:\DEVZW=TEWN92C;S7?3\?Z^XSV4@?-@KTS]21SZ<8YZ9/7I4)1EZ
M?,/_ !X?AW[>_7VJ^\9 ^7)'<$Y/?GDC/';/7!'>H63JR]^J\ <<<>A]C^.*
MM-25U_P5Y,QE#L9YC&,I^6>#_/''I^-0N@;J-K\ $Y[$GCID$!N1U&?3B^R
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M .PII7_J,Z%7I^D-C2M*W<J--L,# R"+2+GJ,C&>.3[>GF/[2/\ R7#XC_\
M83TO_P!1C0O\^OIS7HND.1I.E!CG.FV X )!^R1#H>H/?OGZXKX3AI-U<9;9
M4J-__!L_\MC]DX_=L/E?_81B_P#U'HO^F;X9QPQRHZG/) 'N!C/4_,<<BI5D
MV@NH.S@$$]^,$8)!SN7/(P!WZ52'8@YP1GYB0<<D=3P>G0_2I Y W@<@ ,A'
M7![>WS9S@YP.F#7U;2>Y^;QEU3^7?Y7U]>GS-&)_[C%L?>)(((R3[Y/7&,=\
MGL;"2!N.C#/![D9!QSTXR,X..<5G))NY7"8QD],^P!P?Q/3C@@U,D@/RN,-Z
M^N >2>.2!GZ''K64H65UKY=?^";QE?R:_J]]-^W0O$9_H1P1_GK]:E27:-LF
M2HZ'C\,\C&,8&.#D=*JJY7[V2.3D#D=.,>G4Y)/H?4S5!O&=]']_];%T$-PN
M"H Y[>PQWXY.<<$$<])$=U(VG() P3P2Q ST/8 \# !X&0<YZLR9VGCKM/KC
M'7L/;IZ8S5I'$@^4A2&Z=^/;((Z@'Z$#@YJ)03U6C_#[M%=]_F6:"L#T_P!9
MQG)."<9/3/& 2 1G&.*=R/O$<Y(QG((YX..U4.<D@X((Y]QC.[.,],\# )(/
M'-6%D*JI8AB0."<8X)('7G  R>X]3BLVFG9E1FXNZV[:V_,NJ^!ALGG[W'0G
MOR#QWP.G-2]<$'W!']/J#5,#&/GW8Q@#'('; QG/^<U(K$ [1_P$\8/MZ<=N
MG3ICE'5"HIWZ/M?5EE25.>2#G(]2?XOK^0^E2*P)#*<'D$?Q#'][&1@D#C.3
MU!QFH%8-T]<8/!]>E+COT/J.#_GZ\5,HJ6NSMNM/2^FMO\^YH70^>.58<CW.
M#D*<G]1P#DCN)E<8&<DY.6XY'.!V/0CJ ./I5 ,6.T\'^$CN0#G/''KCN,C/
M>IP^WACQ_>ZD=.#^&<$GT!]3BTUH[7Z?H_\ @#3:=T7L],\9]: 67.TXSV/3
M/K]:KJQ'H0V 3G@<D9'KR?;I^4P(R1G/3W/?/3Z>E!K&2?DRPKAN.01V.,XX
MYX)XYI2 ?\C^H/J>E5^O/(([]"/\\'!]JD5^<-UQP?7&>OIU'U)_ !18#]GY
MR>N!C&,\C.>Q[&G8# %<8S[@'J.WO47!_P _R(H5BF1C</3/(.<]^G7GDY.#
MQS4.+3O'[OZT E&1]TA3T(SU(.!Z^_YU,A!4[%XSP.!R IYY/?Z_3M48(8 ^
MH!QUZ]C3<8XR>G7G&>0<XXXXY//O1=2T:L_ZZ]/U-(SMI+7S^>M]V_\ +39E
MD,"=IP&_N]??T';FG?Y_S^55T;#!>.,\D\G@D9..G('7M^%2[L')88YX';IU
MY.?K@?K4N#6VW]:>9>R]VSW?*WNGT3;]Q+1K2RM:RU'_ .?Q'(IRL0>23Z^_
M\A3.Y'L/US_A2U T]FGITW5_D[/[T6 <C/K28]R/R_J#4%3!P<]OQZ_2@UC)
M/1_\.*"0>_/0\>GX>_;\:E#@ 9R3_GWJ+@_Y(/\ 0_Y-(25'J.V2<^N.A^G6
MG^#^X&FG>/7=/;^OD6J*A5L=LYQ[5(K ^Q],TAJ2>FS[?U8=11104%-9<],9
MSU_"G44":3T97/!(]*3 /4 _A5FH2I!XR?PH,W%QU3?RZ$9&.R[<C@]LX'T'
M//YU'L).0>OTQCVQD^F,]O>IJ3'N>I/;N<]P:=[[[_/^O\P33TETZ_Y]2"BG
MNI;!R0<8 SMYXXP0<@'WZ'%,P><C&.O<=CU_'\Z&K$N+7FO3_A_Q#_/^?K4;
MJ".@X#8/3!(&#Z]NU24F.ON,?S_QH3L[_P!,G5)VNU>]K[=]7>Z2UC&VEK+=
M%<JZ EBI'&0"<\D#C( Q_P#7H!R._.><^YXX/\N/0U.1A2% )X.">.HZY]A4
M6S))W;2>"J@$#@#/Z<G'!XSQSHG&>^C]?U_07+?WH7O\5M4G?IRZ:>JT:UZ$
M;("/<#Y3D\'\.WJ,=/PJ(Y4@$<GN.1W_ !YQQD5*,G.<#( [CCG/7J1GZ>].
M(!&",BEK#?5?UL+1NTE9I::[W6]TNG:_W$%%*RLN3RP]<#(Y/8>V,''4\X%-
M'3_.?Q]_7WJTTU<S::?ZD3(1RHX[K_\ $_S(/Z4T$'I5BF,@;GH?4?ID=\>]
M,169-W3"D\D]SCH.WKG.>W0YJ%UQ\IYW C=UZY'4XR03T[ YJT?E.&_/L1V.
M>@^G'/X4A (P?\_X?6FI->:>Z_K^F3**EY/R_7O8HLK+SD%1CD\-R0/3'!/Y
M5 4(Y7I_=_F5Z^V.0#SP*O,C $##8ZEL^QZ $D $<_RQ46P'D$J3\Q'7 .<C
M!X')].V*M6WAOUC?3O9=$_.STT,G%K?:[L^_^5_,I$'/'&.HZ<^X _\ UC&#
MBFLN[(^4-U4CZ\^_.,'V-62H89Z-CKR"/PXR,^O!J%E(X;H3P1WP1U]">/Q_
M*JC)2\FMT_TVN92AUCH^W3T2T2^\K,!]UP,CU/7&0"#QGO\ X5"R;<!L%>@)
MZYZ\^A]"#V]:O<=",XX!VYXQZ@?6HF3;TRRGMC..F/7(///;@5:DUZ=NFN^F
MQG_37X%%E.>.GIZ_B3P?3C'09&>(60,<@X/<CG...0>./SJ\8^Z'ZKG(/3H2
M>,#IZ\=JA*ACUP?H>1]#C\_PJ]'=P=I6U73TL[+?KVT,Y0ZK[OZV_(SW7. W
M##H0>Q[C.,CV/H>N,&%E[,./X6Z9Z@$=,'^?4<5H.H.5/![''?J"#QG'7&?8
M]ZKLFWCEEZ'US@\8PP QCD#V^E*5WRO27;_@[:_\#<QE%/=-/[OO109" 0P#
M+Z@<8'=AV]>,@>O&:A9".4Y'IW'^Z>_?J> ,"M!EQDCE>.!R0.GOD=R>O/0C
MI R9)*GTR.,'L?IP/S%6I-?Y/;ML9.+6YGNA8Y4X(P,'ID9Z\$@X)XQ431MP
M7.>H&WJ#C/< 8XYY_ U>*!N?NL,9QZ\YX/7J0#_/I4++N^5L@@YX/UQ@]^#S
M]><=*M6=W'1[V[_DMR6DU9I/Y*_R=KKY,SV3H'X) *D''7'0]0>F1T/45"R8
MR&&Y>N<9'XX'&/7ICN#6B(LD@_=SP,YXR?4''&!CC/K5<J0"<#;_ '><@8[9
MZ^F/7@<8JU+6ST?X/;;_ (?R,)T^JV3W]>ZWTVO\]F9S1L.5.X>G4X((X&"#
MVY[C=U[UWB+#((7'(4]!@8Y(R/7.!QD@$X%:;)W0_P# >V<\^X^GKVJN\:L>
MNU^0/]X ]O4<'(ZX'45JI_S?><\H]&OGI>WD[.QDLH)^9<$#G/! R>^?7((P
M.,\]JB8 ,>,+QCL,8SP?<Y(SU&<<9K49%8_,"&&!SVY)QSP03Z=1P,55DC89
M9L8) X&0"!C))! 7@G& ><'&2:T_I&,H->:?6WX=?OV*6 V00"",#(.2/3)X
M(QGH>1SZU"Z%<G&\8QC)ST'.,8'3DY/..G-7&#;5P/E !S_P$@@#OC/UPO<F
MHLXZ D=^N1Z8!_E]/:J4K)I[-.W=.SZ[ZZ>FYC*'9=[K_)?><7^TE_R7#XD>
MVIZ6?R\,:$:[K1Y2FEZ63SG3+ D8SUM(B.<\#KGJ>F1BN%_:2_Y+A\1QW.IZ
M6!Z?\BOH?7KQCV_QKLM+=5TG2QR<:=8 D=/^/2(CKC(."./?)%?&\,?QL;_U
MZH?^G:A^K>(;:P^4V?\ S$XO3H_]GH[_ -=CH5< [E)P" 0!PV2 ./QX..<Y
M&0*L*X)!!PW3'!QU'3@D'/7Z$@5E(VW#)@\''H>WT!]?7D'GD64DW8ZB3^G7
M ZXRH(SZYYZ9^M<$]M#\SC._D^WZKRVOY^1H!SD;R  #SCJ??CC@]/5<U.LC
M ;3TZ;L=%Z YYR0.3QZ^E45D/&\ ')P<\< YSC(SU[8Z\# J4%MO#$#^'GMV
MYQTQCCJ.>36;36C-U)->];^OR+ZRA!D'<@'7DX/.?7'\.!@#DFK".5Z,&)ZJ
M. .1SCJHQU.#DGTQ6>K[2&&=G&X<9!Z$G/L5).> N>AR94=>/*ZYY'3@'GDY
M'H<9^N.:S<$]K+\C>,^DO2_GW;OMZ7Z>9IJP89!^H]#T(_,$9Z<&G=\@D'U'
MIZ<YXJDC*3Q\KY/3@Y&02.HP>3ZD')[5863H'PI]>WT)]>OM@9XZ5FTT[,VC
M*WFOZV+:2Y 1SC/&1QP.>.N<XPW0Y/?@U/QP!R2.N.H&,DD#OQSZG(JE3D=H
MR<#(/7J3[#'&>>,YSR<YQ4RBI*S^3[&J::NB^K;2,C(R, #D$$!<=R.,8R3Z
MD\U:!!^;&7Y^4'KSCC(YXYJBK J#&,@,.,C''/N#U!'OCT(IVXA@V3NSU'3H
M!C';CD\@XR0>QR<6O-;WMT\^B_R*3:U3L_(O*22#C:>2"1R/;.>>"<C_ /74
MRN<@,<'H#V;)/'L>1U]#CO517W#,F<'!4*3P#W.,$X!_1L U(-_\73Z@\=\\
M9/%2;PJZ6E=N^]^]NY<YR"#@CIW[$?R-.#L#\QR#UXQCIS]/7\ZK))C.<L.V
M.2,=N0,]O7'J><3 ANA!YQQZT-7T>QT%A6QRIRI[?PD9YQZ'^?YXE1NZY!!S
MCCN"">H!!SC@\8[<BJ8R#D'!_0_4=_?H?>I ^[CE6 YP,\=\>H/ /IG)'%8R
MA;5:KKW7GZ=P+ZN" 2?F).[KTYP<=N-M2\$>H-4EDZ!N#TSCCIU/8<\?7G@'
MB8,!G<"1@8XSC&<_3M[5/Y%QG96?R+ 8KTY'IG&"<=#@\>W;K4JL&Z'TR.XS
MV/O4 ..#V YS^'?'I2^X.#V(Y_\ K$9 _*@UW)B#G*DKGKCO^6*F5P<AL DX
M &>00/\ ZX_"H%?)P>#V]#]/RY!Z>IZT\\TG%/U[@3$?4]."2>_/4XZ4?=Y4
M<G((QGZ\?48X_P *B5]@"G@ G)P> 22.@QUP./6I@%(R .><XP>>_K_6H4G'
MXDVKZ/\ X?H.,G%W7S7?^MT3A@02"#S@8[\ X^O-*,$9&>>N?4<?R JL"1D
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M,=5X//'9CVS_ /6]34?0X/!]/ZCU'H:-M5OW#?1[%)DY._[V %/(ZY P <$
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M9<'_ *]HL]<X./R].]<O^TE_R6_XD>^I:9_ZB^AFN@TU@=/L"IPPL;/(]?\
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M,KUQCU ZG.!,&S@ ;&&3S@@X[9!!YX[=N^*STDR=RD;NZ]L#KU ).TY'(QD
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MMTTU=6[/OZ-V:*;"'ED2&-#))(52*- 6>1V(5$11DLS,0  #R0.XS^3OBO\
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M *_%#2,\'&>,''OT_P GO41!!Z<9P#[\]1V'![^GK4QYSP>".0.G( YZ#)X
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M&\5:OH^J>'[CQ=X=MKOPW^P^H?\ !&7X<^*O^"/WA7_@DAX^^-7B37=$\&:
MD&@?M!^'_ UIX4UZQ\9:;\8_$?QB\/>*A\,;GQKXGTFYTRRNO$-QX1UOPK?>
M-KLZYX>GU2YT_7_#/B"ZTC6/#WF/P4_X(M?%GX??MD_LC_MY?&3_ (*4_&']
MJ?\ :&_9K\/?$/X<>*M1^+?P5\-VOA'XB?!OQ7X"\1?#KPM\/O /A_P]\4+;
M4/@KJ7A/1O&OC?6]<\<:GX@^,E[\0O''B"/Q3JNBZ1+:ZI9>(E['%*6'Y?:6
M2I.H_;2;O*:]LI<T[;=$I)QNURVLZ5? 3IXU3]@G*6)AAX_5:</W<:;6$=*I
M"CSQU3NYSIS4W'G=2,[T_P C?V3?!7[9_P *O^"KO_!>GXA2?MNKXB\1_L[_
M +/FL^/_ (QW;_LT_"73_P#AI"^G_9:^(^I_ &V%I<R:UI/PA3X ^)W\':^1
MX<TSQ!8_%1/!W]C>-M-DTK7]3MS[7IG_  5?_;F;_@BS_P $MO&OP^\7>$=9
M_P""@7_!2?\ :7\6?LP>%OC=XJ^'7PSTGP-X"NV_:F^,WPZLO&<_PY\-^$K/
MX=C6[+3-,^&_A32[1/A?K'AV33Y_%/B[Q!87WBFSL(_$/ZA>+O\ @C_KM_\
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M' P>,YZY(^4]^1960CAE( _B]LGD_48)QT).1Q64I)!;D<\8.3D'G!/J1@#
M&!TY-6(YB,!ON] >  .WI[ $\$8Y!)J7%/?[T:1GTEOWZ>KUWWOIZ;FFKX^7
M@IWZ\ \$>F!U(]#Q4J,%Y4[QR OH,]!WXZ9/09Z]*HJ^SD?,G5CD'L 3GJ2
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M*1^1[8/4'@@GMG' J4<C/8^G< DK@]1D=?RK*4&KM:K\?N_K09?'4KRP/?C
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M>TP]*FZE6C3=>I*FZU6C2]M.G"2I2I0?(U&#Q%;#QJ5&J=-RD?TP@C&[!VC
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ME2V@9OBI8_!-1_PKV3X<+\79/^+I:A8^%,P_#Z4!Y_[;)/AJ*;6H_*_VKO\
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M)==D_-;+7M=[;]%7HI2I&,?,./J.G/'4<]?8\\'"5::>S_KTW,W%K<B9".5
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M1.-*44Z,(IR3_!7X0?MM_LJ?\%3?VO/VBM0_8A_9OUKQ'XXL/V-/$WPZL?\
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M#\7>*+'P;\6[KX=:QX*UC2?%/IW_  2M^/[?\%+O^"FG_!4O]KJ^T;0?@/\
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MDV7Q$OO$D/@2'QDGA>T\4>)-*T#Q)?>#4\17GAZ+2[C#U30?A]XC_P""2?\
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MYJ$6H>(/#_G^(9YKW5;/P=8^++74]=TKQ38:O=?GQ_P6_P#%/[$GA#_@N_\
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M9 ]3UK,64#Y67<1W ^\",C'!' ..6YP,9S@6%<KR3D'/ Z#D$ 'G)'(SP#W
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MJD&N:CH/Q@T'5].@M8$LM67,_P""%W[0.A_#7X%?\%+OV$/AW\6O"?Q4TO\
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M.&S@'WSG()&2?QQGO_+Y^SI^V=_P4H^'7[:7_!4/]BC]J#]HWX>?&^3]A?\
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MJ1'Z9SCGC SG/?\ 7O3,CU_P_/I1CG(]^,G'U[_RYS3_ #[_ -:?,IKK'?\
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MJE1U;!Z'H/?GMGKTSCZCGFHE%/U[F].ILGO_ "^7=>GYFCGG<.&).TXQU!)
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M@,2.3AO7G@'WSR#C&!]:G#$#!RR\8/4]_O$9/I@@=L'KFLY9,<-RIZ'.[MD
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MQ?$#]A#3?^"KWQ3@_86U'Q'X@\<?#/X ZA^SQX#GU30/%=YXDL_%GAFT\?\
MQ+M_%\/B7Q;X'T'Q);_\)EK7@'PVO@OP/XG^(,(\>:=X;\&^([^]NX*__!8?
MP#\,/V6X/^"5GQ+\2_&C]H7]D_XL_LN^"M*^"/@#_@I7\%_@5;?&OX5^!9?
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M/K%A8/?I=64<UE/W2NRC .8R02 21QG!'KCKCH23CYLDSALC*GJ.QY!QGD=
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M5HDOYY_V4_\ @A)X[^#GCW]E=?VA?^"A?Q1_:H_9O_8-^*>O?&G]C[]G&_\
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M$'IGV_#UJ8.#Z >N?_K4[?U_P04NDM'MY/Y[?B/HHHI%!00#U /UHHH B*$
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MU70O*XR""V_^Z!QG!XYP#@9/WN>HZU.&! W?*V2!Z\@XY&?7UZCJ>^<K$GC
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M8Y&<]QZ'VZ57#L#R=P_#=^? _P#K?3F8$$ CH:32:LQDX(8 ^V<9Y'Y<]Z0
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M'W@""2"..GX^F:KKU'U'\ZGK+H=)864_Q8(SUSR/Y9 ]1R>V:LI(5Q@AESR
M>H).><X.#G /IC/7.=4J=#]?Z"E:Z_KJ;1;7*V[M]>NEWZ&NKJR]0H!YS@>X
M(&1CG')'.",#LY6QAERIXP=IS@'H>.^!WR,<=35&+_6'_=;_ -#JQ4.G:^OG
MM\^YTQNTGIK;OUL7HY"Q^8?,#UP1P!WR!] <$Y !Z@U/G)P>3UQT XZ\@'/I
MZ9]LU1/3\5_F*LUA**>NE[63UT_$UC%IW36W57ZOS7;I9^?>TCLG&<J>H.<@
M'KVR<9SZ\8YZ5:23(W X['KCK@@@#@8QC(![=JSX^_X?UJ:/[Y_W1_,U#@TK
MW7W?\$ZHIQZW7;_)FBC@C((4@\X!Z<]/7\0<<\8P:G60-A6/S8X8=_7!['U!
MQZ51B^^/P_F*LG[GX+_2L)I:/Y:>G];&T$[7OU>A=23##=ANIR.IX.,CD8Y)
MR..W'6K E^8YQM.,=/ER 1GGW.?0@]NE'_EG_G^]3HON'_@7_HRL^G7\.]CH
MC3;BW=*T'*UGK9K3?SW-%7*9VMG.20.YQ@'CISST]B3U-M7W?,&VGIC!)P,]
M!P1][!)!!/3H"<N'[W^?0U:J'))VM?I]]O\ ,F,G'S7;_@FB) W!;#'OCY>G
MX$$CMGJ<9/2IE?:1EMP'49''H0"<\8]2<'N>N4_WC^'\A6G'_JX_]Q?_ $$5
M$E9V1HJC2O;K:WIKV\R</MP-P9,C..3QC[V">@&21@$\$8)JRCC 8#C/*YXP
M3@].V!N__751OX?]T?UIT??\/ZU%[KUNOS7Z'4FUJG9[?+YFBC;@"I*D$CMR
M.O SC&<9..<$8':=) W!X(Z^G7L3[<UFI]X?C_(U;;JGU_J*SE%)^O,_N5[&
MO.[)VU;MOVMK^I:/S#@]^W^3TZ^_3(SFI4D*D!LLO;.20<CM@D\9P?4X/K40
MZM]?Z"EK#G\OQ_X!O&;;2_$N!LDG("XP.>3U&>^-IR1CKQR*>C$,,,!D\X^A
M.2./8<\Y)]J@B_A_'^M6*EM/I9][_IL:%A6W?*&"L.=P .[CD<]2<YXR.W:I
M,A2 S;B?3CD=>_&<Y[#@CVJG4Z]!]!_*I*C)Q::Z='MJ6E<KP?F XR.HQT!
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  A L # 2(  A$! Q$!_\0
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MQ<^(5A\5-<M8-2\/Z[X*\.P75]KDEKH\\,UFHC:2WLDG-RR2W)7:SX0!5P2
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M:Q-;FT/]G'^V[;P%?*-6U0:7!:^$-0O7DL+*6YO19QWVPDR11L\F'"$*YAX
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M]P]G#LCZ-_X1_3/^@?:_]^5_PI/^$?TW_GPM/^_*_P"%?)6C?&+XA_$+Q/\
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MDAM,\/7\5I;!8;F2*2+4YF$5T_\ HX#*D8!RQ4X7)/:/N'L(]D?17_".Z?\
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M5@O!+)Y_VJ<,)Y&DW;GWAB"K$J0$&,(N)O\ B;_] +4_^_!I<ZO_ - +4O\
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M?@=X"M=#U32GTF>]AU.2"6ZN;_4;FYNW:!MT#+<R2-*AC))3:PVDDC!)IK?
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MPY8$@9SC-9'_  F&M_\ 0LZC_P!^C3O^$RUO_H6=1_[]&ER+N'M9]F=%XL\
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M-<&:3?NG\QE5G\TMN*J3T%=1JGAG2=:US1=8O;03ZCHSRR6$Q=AY#2QF.0@
MX)*$KR#C)Q7'_P#";ZW_ -"QJ/\ WZ/^%+_PG&M?]"OJ/_?L_P"%/D7<7M)=
MF=9H^@#2=>U[4_MD\_\ :LL,OV>21FC@V1+'A 20N=N3M !)Z9R3Q5G^SCX
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M/^%'+YA[1O=/[CT/*T?+7GO_  GVM?\ 0JZA_P!^S_A1_P )]K7_ $*NH?\
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
